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1 Introduction 
1.1 Radiation treatment in cancer and normal tissue toxicity 
More than 50% of all cancer patients receive radiotherapy (RT), at least once during 
their disease [6, 32]. Therefore, RT is one major treatment option for tumor patients besides 
surgery and chemotherapy. However, most often different treatment modalities are combined 
to achieve best tumor control and quality of life [78]. 
Radiation is applied with high-energy photons, charged particles like protons or heavy 
ions. RT is high effective in tumor cell killing because of its DNA damaging capacity. 
Especially DNA double strand breaks were identified as main contributors to the tumor cell 
killing characteristic of ionizing radiation (IR) [95]. RT triggers the generation of free radicals 
and reactive ions, particularly hydroxyl radicals. These molecules can cause further damage 
to cells resulting in a cellular stress response or cell death [13]. Due to its high potential to 
eradicate tumor cells, RT is one of the most effective cancer treatments [6]. 
Although there has been much technical improvement to administer the IR precisely 
to the tumor volume and spare as much healthy tissue as possible, normal tissue toxicity 
remains an important dose-limiting factor in RT [6]. The tolerance of the normal tissue to the 
toxic effects of IR is normally higher than the sensitivity of the tumor cells. The difference 
between the dose-response curves of the specific tumor type and the surrounding tissue 
defines the therapeutic window of RT (Figure 1) [78]. High intrinsic radioresistance of tumor 
Figure 1: The therapeutic window in RT: The therapeutic window is defined by the difference between the 
probability of a certain radiation dose to kill the irradiated tumor cells and the probability to damage the normal 
tissue within the irradiation field. The wider the therapeutic window the more effective RT can be in tumor control 
and normal tissue toxicity (left part). Sensitizing tumor cells for irradiation and protecting normal tissue from 
irradiation can help to widen the therapeutic window (right part). Modified from [78] and [44] 
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cells, for example mediated through mutations or hypoxia, aggravates successful therapy 
outcomes [97]. Thus it is favorable to combine RT with other therapies to widen the 
therapeutic window, by sensitizing the tumor for RT-mediated cell death and/or by protecting 
the normal tissue from adverse effects of RT. 
The lung is one of the most sensitive organs to radiation-induced damage. 
Nevertheless, RT is a standard treatment option for patients suffering from a neoplasm in the 
thoracic room e.g. lung tumor, head and neck cancer, or breast cancer. Also, patients who 
receive total body irradiation (TBI) in conditioning regimens for stem cell or bone marrow 
transplantations receive irradiation of the lung [69]. A major challenge for treating lung cancer 
is the high radioresistance of the tumors mediated for example through high intrinsic repair 
capabilities, hypoxia or a large tumor volume at the start of the treatment [159]. On the one 
hand, RT aims to achieve highest possible tumor control rates, by applying high radiation 
doses so that normal tissue toxicity cannot be excluded [122]. On the other hand, the high 
radiosensitivity of the normal lung tissue limits the applied dose, thereby enhancing the risk 
of local relapses and reducing tumor control [159]. 
Adverse side effects of RT are generally subdivided into early or acute toxicities and 
late or chronic toxicities [20, 69]. Regarding the normal lung tissue, side effects include acute 
inflammatory responses (pneumonitic phase) as well as chronic inflammatory responses, 
tissue remodeling and fibrosis development (fibrotic phase). Particularly these late side 
effects limit the total dose that is applied during the treatment as they are of a progressive 
nature [20, 156]. Radiation-induced pneumonitis and fibrosis are life-threatening adverse 
side effects of RT, but currently there are no therapies for a complete prevention or treatment 
of the diseases available [47]. Although already a lot of research has been done investigating 
and improving the direct damage of IR to tumor cells [38, 89], the side effects induced in the 
irradiated surrounding tissues are still not well understood. Consequently, there is a high 
need for the development of new treatment approaches to reduce normal tissue toxicity in 
RT. 
1.2 Radiation-induced pneumopathy 
1.2.1 Radiation-induced pneumonitis 
Radiation-induced pneumonitis develops usually 4-12 weeks after radiation treatment 
and occurs in 5-20% of patients with lung or breast cancer in the irradiated and non-
irradiated lung regions [47, 90, 119]. For patients receiving TBI the incidence of radiation 
pneumonitis was shown to be higher than 30% [69]. The damage of the lung tissue depends 
on the dose and volume of the irradiation field, but also on patient related factors like age, 
gender and performance status [122]. The symptoms of radiation-pneumonitis range from 
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low-grade fever and nonspecific respiratory symptoms up to dyspnea, non-productive cough, 
and chest pain [90, 119, 122]. During this acute phase of lung injury a massive infiltration of 
lymphocytes, monocytes, neutrophils and macrophages and subsequent changes in the 
cytokine and chemokine reservoir has been described from others and our lab [2, 17, 65, 
125]. For details see section 1.3.2. Up to now, no causative but symptomatic treatment with 
glucocorticoids is available, which might reduce inflammation and inhibit endothelial cell 
toxicity [48]. Other anti-inflammatory agents (Azathioprine and cyclosporine) were shown to 
effectively dampen the symptoms of pneumonitis and could be used if glucocorticoids are not 
suitable [48, 110]. 
1.2.2 Radiation-induced lung fibrosis 
Radiation-induced lung fibrosis (RILF) is the late adverse effect, limiting the treatment 
dose and enhancing the risk of tumor relapses simultaneously [20, 156]. Fibrosis 
development can occur in patients, who did not have pneumonitis before or were 
asymptomatic after acute pneumonitis [160]. Pulmonary fibrosis appears around six months 
up to years after irradiation. Major symptoms are breathing difficulties due to volume loss of 
the lung upon massive collagen deposition [20, 90]. So far, no treatment for patients suffering 
from RILF is available, but different approaches are in experimental investigations [20, 90, 
160]. 
Fibrosis is characterized by accumulation of extracellular matrix (ECM) molecules in 
the lung tissue, leading to tissue scarring, progression of volume loss, and subsequent 
reduction of breathing ability (Figure 2) [165]. Fibrotic areas are mainly composed of 
collagens and fibronectin. Both proteins are known to be synthesized and secreted by 
fibroblasts. Various cell types are thought to impact on the development of RILF. One 
example are myofibroblasts, which can either derive from fibroblasts, circulating fibrocytes, or 
through epithelial-mesenchymal transition (EMT), a process in which epithelial cells undergo 
a transition to fibroblasts or myofibroblasts via migratory mesenchymal cells [120, 146, 161, 
165]. Furthermore, radiation-induced damage to resident lung cells may lead to a delayed 
death of bronchiolar epithelial cells and result in a loss of barrier function [34]. Immune cells 
are recruited to the irradiated lung tissue and have been correlated to pathologic actions in 
patients with pulmonary fibrosis [65, 146]. The underlying mechanisms leading to pulmonary 
fibrosis are still not fully understood and although it is thought to be a deregulation of repair 
processes, potentially resulting from chronic inflammation, the contribution of the different 
immune cells to pathogenesis remains elusive [12, 16, 83, 165]. A detailed analysis of the 
different immune cells is described in the section 1.3.2. 
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1.2.3 Model systems to study radiation-induced normal tissue damage 
The development of radiation-induced pneumonitis and lung fibrosis is a multicellular 
process that includes the complex interaction of various types of cells and soluble mediators. 
Model systems in the cell culture including two or three different cell types are not able to 
mimic the ongoing processes in the human body. Consequently, it is unavoidable to use in 
vivo model systems to study radiation-induced lung toxicity. One possible and most often 
used model organism that is also used by our lab is the mouse. Therefore, the following 
section focusses on murine models to investigate pulmonary fibrosis. 
The most commonly used model to investigate different types of pulmonary injury 
(e.g. idiopathic pulmonary fibrosis (IPF) or chronic obstructive pulmonary disease (COPD)) is 
the bleomycin (BLM) model of lung injury [102]. BLM has been shown to induce lung injury 
as well as fibrosis in many model organisms like mice, rats, hamsters, dogs and primates, 
but is mostly used in murine studies [99, 102]. BLM is an antibiotic, produced by 
Streptomyces verticillus and used in cancer therapy, due to its tumor killing ability [54, 96]. It 
was shown that BLM induces single and double strand breaks in the DNA. Therefore, it is an 
useful agent to mimic irradiation-induced damage [137]. 
The model of BLM-induced lung fibrosis is separated further into different models. 
One intratracheal (i.t.) instillation of BLM leads to an acute lung injury (acute model) and to 
the development of fibrosis within 14 days which is mostly located bronchiocentric [23, 96]. It 
has been reported that in contrast to the human disease fibrosis can resolve in the i.t. model 
Figure 2: Schematic overview of a healthy lung and alveoli compared to alveoli in pulmonary fibrosis. The 
tissue between adjacent alveoli is thickened and irregular. Large areas of fibrosis, which mostly consist of 
collagen, can be found. The structure of the air spaces is irregular (http://www.mayoclinic.org/diseases-
conditions/pulmonary-fibrosis/home/ovc-20211752). 
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of BLM-induced lung fibrosis [99]. More recently, a model of repetitive i.t. injections of BLM 
has been established and it was described to mimic the chronic aspect of pulmonary fibrosis 
more accurately [31]. Several intraperitoneal (i.p.) or intravenous (i.v.) injections of BLM 
result in lung inflammation and a more lasting fibrosis development around 28-33 days with 
subpleural scarring similar to the pathology in humans (chronic model) [23, 174].  
Another in vivo model to study radiation-induced lung injury is a radiation-based 
model with a single high dose of IR. Thereby the mice undergo either a total body or whole 
thorax irradiation (WTI) with doses ranging from 12 to 15 Gy [99]. The irradiation model 
mimics the pathology observed in the clinics with a pneumonitic phase, one to three months 
after irradiation, and fibrosis development, after more than 6 months (24-30 weeks) [61, 99]. 
A disadvantage of the irradiation model with a single high dose is that the irradiation dose in 
cancer treatments is usually applied in fractionated doses to improve cytotoxic effects to the 
tumor and reduce normal tissue damage [19]. A more suitable model would therefore be a 
fractionated model. However, fractionated models of thorax irradiation are so far only 
reported in studies with rats and not mice [151, 153]. In the future, it will be necessary to 
establish also adequate murine models with fractionated irradiation schemes to improve the 
clinical relevance of the model. 
It has been shown that fibrosis development after BLM treatment or thorax irradiation 
is strongly strain specific. In the model of BLM-induced lung fibrosis the murine strains CBA 
and C57BL/6 were shown to be fibrosis-prone, whereas BALB/c mice were fibrosis-resistant 
[96]. In the model of irradiation-induced fibrosis C3H/HeJ and CBA/J were shown to be 
fibrosis-resistant [99]. BALB/c mice developed only small areas with mild fibrosis after thorax 
irradiation [61], whereas C57BL/6 mice are reported to be fibrosis prone [60, 99]. All 
experiments in this project were conducted with the fibrosis-prone mice strain C57BL/6 and 
by irradiating the mice over their whole thorax with a single high dose of 15 Gy from a 
Cobalt-60 source. 
1.3 Driving forces of inflammation and repair processes upon 
irradiation injury 
1.3.1 Soluble mediators 
Initially, IR causes DNA single- and double-strand breaks as well as reactive oxygen 
and nitric oxide species (ROS and NOS) [13]. ROS and NOS can induce further DNA 
damage or damage to ECM components. Even more, these highly reactive molecules initiate 
stress responses and immune responses. Unrepaired DNA damage might lead to cell death, 
which in turn causes an immune response initiating the elimination of damaged cells and 
debris and the repair and regeneration of the wound [134]. 
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Danger-associated molecule patterns (DAMPs) are endogenous molecules created 
and released upon tissue damage. Examples for DAMPs are heat shock protein 70 (HSP70), 
high mobility group box 1 protein (HMGB1), surfactant protein A, adenosine triphosphate 
(ATP) and hyaluronan (HA) fragments [112, 149]. They are known as key molecules in the 
initiation of tissue repair. DAMPs act via toll-like receptors (TLRs) and lead to two main 
intrinsic pathways depending on the receptor and the associated proteins they bind to [149]. 
The first pathway leads, via several stages, to the activation of nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-țB) and results in the expression of pro-inflammatory 
cytokines. The second pathway results in the synthesis of pro-inflammatory interferons (IFN) 
[112]. However, DAMPs are reported to be highly upregulated in many pathologic conditions 
revealing an important role for regulated DAMP secretion/production [144, 149]. 
Furthermore, irradiation induces rapid changes in cytokine/chemokine expression and 
redox-sensitive proteins, where the latter could be a result of pro-inflammatory 
cytokines/chemokines [128]. Generation of ROS through cytokines causes enhanced cell 
death and DNA damage [128]. The main goal of cytokine/chemokine release upon irradiation 
is the restoration of tissue homeostasis as well as the orchestration of cell communications 
between mesenchymal, epithelial and immune cells [128]. Cytokines, chemokines and 
DAMPs work closely together to fulfill this task. [108]. It is also known that cytokine cascades 
that are initially driven by DAMPs drive inflammatory tissue damage [129]. Release of 
cytokines, chemokines and DAMPs trigger immune cell infiltration to the damage site. During 
regeneration anti-inflammatory cells infiltrate to the tissue and help to orchestrate the 
substitution of damaged areas by secretion of ECM components [128]. The first cytokines 
being released are among others interleukin 1, 6 (IL-1, IL-6) and tumor necrosis factor alpha 
(TNFĮ). Those are able to activate especially the resident immune cells like lymphocytes and 
macrophages [128] and can be found increased in plasma shortly after irradiation [119]. 
Mediated through cytokines and chemokines, adhesion molecules on the endothelial 
membranes are upregulated to facilitate the infiltration of more lymphocytes, monocytes and 
macrophages into the lung tissue from the blood [119]. 
1.3.2 The Immune cells 
Irradiation within the thoracic room leads to an influx of diverse types of immune cells 
that orchestrate a complex interaction with resident cells as well as with each other. Among 
them are T lymphocytes and myeloid cells/ macrophages which are in the focus of this 
thesis. T-lymphocytes as well as myeloid cells and neutrophils were found to be elevated 
after radiation treatment in breast cancer patients [85]. We and others showed in a preclinical 
mouse model that WTI leads to an infiltration of activated T cells [17, 22, 64, 105]. Similarly, 
in a study with rats undergoing hemithorax irradiation an influx of CD4+ T cells was observed 
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at 4 weeks after irradiation. A depletion of those cells resulted in reduced alveolar thickening 
[157]. In a patient based study RT also led to an increase in CD4+ and CD8+ T cells in 
bronchoalveolar lavages (BAL). Patients who were later diagnosed with pneumonitis were 
characterized by higher total cell counts and higher proportions of T-lymphocytes [105]. 
Similar results were obtained by two other studies analyzing BAL samples of irradiated and 
non-irradiated patients. Interestingly, pneumonitis could be detected in both lung lopes 
although irradiation was limited to one half [85, 121]. Also in a murine model, inflammation 
could be observed in all lopes of the lung although only the right hemithorax received 
radiation treatment [35]. Taken together, the data suggest an important role for inflammatory 
T-lymphocytes in radiation-induced pneumonitis and indicate the inclusion of systemic 
effects. Our lab could furthermore show that the loss of mature T and B-lymphocytes in 
recombination activating gene 2 (RAG2) deficient mice was accompanied by an early onset 
of fibrosis [17]. Moreover, important roles for CD4+ T cell subsets in pro-fibrotic actions have 
also been proposed, for example through the secretion of IL-4, IL-5 or IL-13 [163]. These 
data indicate crucial roles for T-lymphocytes in early and late events after WTI. 
Besides lymphocytes also myeloid cells and macrophages infiltrate into the lung upon 
irradiation [17, 63, 87]. Macrophages are the first line of defense and responsible for the 
orchestration of the immune response. One of their major functions is the phagocytosis of 
apoptotic neutrophils that infiltrate into the lung upon tissue injury [56]. In previous studies 
from our lab hemithorax irradiation of C57BL/6 mice led to increased levels of various 
macrophage-related cytokines and chemokines in BAL. Elevated mediators include 
macrophage-colony stimulating factor (M-CSF), macrophage chemoattractant protein-1 
(MCP-1; CCL-2), macrophage inflammatory proteins (MIP)-1ß and MIP-2. Moreover, 
irradiation led to the formation of lipid-loaded macrophages, indicating a disturbed lipid 
metabolism [17]. 
Alveolar macrophages infiltrate into the airways shortly after birth. Once in the lung 
tissue they are known to be able to undergo self-renewal [50, 52]. But in the case of 
depletion of alveolar macrophages through IR it has been shown, that circulating monocytes 
can contribute at least partially to a repopulation [86]. Pulmonary macrophages are the first 
line of defense, phagocyting cell debris and pathogens [81]. In general, macrophages show a 
high plasticity and rapidly respond to changes in their microenvironment [45, 56, 113]. 
Therefore, they have been subdivided into classically and alternatively activated 
macrophages. The classical activation refers to a pro-inflammatory phenotype and is also 
named M1 phenotype, whereas the alternative activation refers to an anti-inflammatory 
macrophage phenotype and is also named M2 phenotype [45, 113]. It has been suggested 
that pro-inflammatory macrophages contribute to radiation-induced pneumonitis, whereas 
anti-inflammatory macrophages contribute to RILF [34]. 
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Activation of TLRs through DAMPS or the cytokine IFN-Ȗ, which is released upon 
tissue injury, can drive the polarization into a pro-inflammatory macrophage phenotype. Pro-
inflammatory macrophages show improved phagocytic capacity and production of pro-
inflammatory cytokines to recruit further immune cells from the circulation to the site of injury 
[56, 81, 138]. A study from Savani and colleagues revealed that i.t. injection of BLM in rats 
resulted in an influx of macrophages [127]. Furthermore, in a study with C57BL/6 mice 
receiving 12 Gy WTI macrophages expressed the inducible nitric oxide synthase (iNOS) a 
known marker of the pro-inflammatory phenotype of macrophages early after irradiation 
[171]. 
Apart from that, the accumulation of macrophages and their mediators is also one 
characteristic feature of chronic inflammatory diseases [91]. The source of enhanced 
chemokines in chronically inflamed tissues (e.g. in patients with IPF [18], rheumatoid arthritis 
[71] or BLM-induced lung injury in mice [132]) could be attributed to activated macrophages 
[91]. Macrophages have been reported to drive fibroblast recruitment and activation during 
fibrotic diseases [164]. The secretion of pro-fibrotic mediators like osteopontin (OPN), 
transforming growth factor beta (TGFȕ) and platelet derived growth factor (PDGF) has also 
been attributed to macrophages in fibrotic tissues [143, 163].  
Interestingly in pathologic conditions that include chronic inflammation, macrophages 
with an anti-inflammatory phenotype were found. Alternative activated macrophages are 
suspected to drive IPF, COPD [173] and potentially RILF [171, 173]. Moreover, macrophages 
in irradiation-induced fibrotic lung tissues were found to express arginase-1 (ARG1), a 
protein that competes with iNOS for its substrate ݱ-Arginine. The products emerging from the 
metabolism of ݱ-Arginine through ARG1 drive cell growth and collagen synthesis. Therefore, 
ARG1 activity is a feature of anti-inflammatory macrophages [171]. 
Prominent roles for macrophages, especially alternatively activated macrophages, 
and T-lymphocytes in the development of pulmonary fibrosis have been suggested. 
However, the underlying mechanisms are not yet understood. Particularly their role in RILF 
remains elusive and further investigations are required. 
1.4 Signaling molecules investigated in the present thesis 
1.4.1 Purinergic signaling 
ATP and adenosine play an important role in the orchestration of inflammation and 
repair in the lung [33]. ATP is actively or passively released upon cell death, damage or 
stress induced for example by IR [167]. Extracellular ATP is a “danger” signal and belongs to 
the earlier mentioned DAMPs [112]. First of all, extracellular ATP can initiate a pro-
inflammatory immune response that leads to the infiltration of pro-inflammatory immune cells 
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[68]. ATP can act via direct binding to receptors, namely P2X and P2Y receptors, or it can be 
converted via membrane bound enzymes [33]. The ectonucleoside triphosphate 
diphosphohydrolase-1 also known as CD39 is an enzyme located on the cell surface of many 
immune cells, like neutrophils [37], lymphocytes [4] and dendritic cells [7] but also epithelial 
cells and fibroblasts [15] or vascular endothelial and smooth muscle cells [167]. CD39 
hydrolyzes extracellular ATP to adenosine diphosphate (ADP) and is also capable of 
hydrolyzing ADP to adenosine monophosphate (AMP). The produced AMP can subsequently 
be converted via the ecto-5'-nucleotidase (CD73) to adenosine. CD73 is found on the cell 
membrane of immune cells like neutrophils [36], dendritic cells [7], macrophages [173] and 
lymphocytes [4] but also on vascular endothelial cells [167]. Extracellular adenosine can 
pursue three different ways: enzymatic inactivation, cellular uptake or action through receptor 
binding. The adenosine deaminase (ADA) can convert adenosine to inosine, a process that 
can happen extra- as well as intracellularly [33]. Adenosine may also be transported into its 
target cells via four different adenosine transporters, the so called equilibrative nucleoside 
transporter (ENT). The third possibility is the binding of extracellular adenosine to one of four 
different adenosine receptors namely A1, A2A, A2B and A3 (from here on ADORA1, ADORA2A, 
ADORA2B and ADORA3) to induce cellular responses
 
(Figure 3) [33, 41]. 
All receptors are G-protein coupled receptors and are expressed on various cell types 
including immune cells [33]. Within the immune cells neutrophils [21], mast cells [84], 
monocytes [172], macrophages [14], dendritic cells [111], T-lymphocytes [57, 94], B-
lymphocytes [43] and natural killer cells [117] have been shown to express adenosine 
receptors. Details are nicely reviewed in a recent publication [15]. ADORA1 and ADORA2A 
Figure 3: Schematic overview of the purinergic system. ATP is released into the extracellular room upon 
stress induction or cell death. ATP can be converted from CD39 via ADP to AMP. AMP is converted to adenosine 
by CD73. Adenosine can be further converted through the adenosine deaminase (ADA) to inosine (extra- and 
intracellular), it can bind to one of four different adenosine receptors (ADO receptor) or it can be transported into 
its target cells via adenosine transporters (ADO transporter, ENT1-4). 
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are high affinity receptors responding to low concentrations of extracellular adenosine, while 
ADORA2B and ADORA3 are low affinity receptors and are mainly addressed if the 
extracellular adenosine concentration rises [33, 41]. Adenosine is known to be responsible in 
dampening the initial inflammatory response in the lung upon stress or injury. Therefore, it 
has a function in the protection of the tissue from massive inflammation [33, 152]. 
1.4.2 Role of CD73 and adenosine in pneumopathy 
CD73 and adenosine are found to be elevated in BALs from patients suffering from 
asthma, IPF and COPD [67]. I.t. administration of BLM to C57BL/6 wildtype mice resulted in 
enhanced levels of adenosine and CD73 activity [152]. Challenging CD73 knockout (CD73-/-) 
mice with BLM i.t. abrogated adenosine accumulation almost completely and led to 
enhanced inflammation as well as fibrosis development. The study revealed a protective role 
for adenosine in the BLM i.t. model of lung injury [152]. In addition, a recent study showed 
that blocking nucleoside transporters with dipyridamole in BLM-induced lung injury inhibited 
the resolution of fibrosis that can normally be observed in the i.t. model. Furthermore, 
treatment with dipyridamole worsened the fibrosis in the chronic model (i.p. injection), 
indicating that long lasting high adenosine levels impact on fibrosis outcome [82]. 
Besides the different models of BLM-induced pneumopathy, the role of chronic 
enhanced levels of adenosine can also be studied in the model of ADA knockout mice 
(ADA-/-). In the ADA-/- mouse model adenosine highly accumulates, due to the deficiency of 
the adenosine converting enzyme ADA [11, 25]. The affected animals die within three weeks 
of age due to respiratory distress [11]. Partially ADA deficient mice also have high levels of 
lung adenosine and enhanced levels of alveolar macrophages are found in the BAL at six 
weeks of age [25]. Severe pulmonary fibrosis and enhanced levels of myofibroblasts could 
be found in these mice at 15 weeks of age. Furthermore, various immune cells like 
macrophages, lymphocytes, eosinophils, and neutrophils infiltrated into the lung tissue [24]. 
Important roles for CD73 and adenosine have been suggested in patients with 
chronic inflammatory lung diseases like IPF and COPD and in the murine BLM model of lung 
injury. However, at the beginning of this project nothing was known about the impact of 
CD73/adenosine on the development of radiation-induced pneumopathy. Database research 
did not show any hits for the combination of RILF or radiation fibrosis lung with adenosine. 
We speculated, as RILF is also a process of chronic inflammation, that extracellular 
adenosine might accumulate in the lung and promotes disease development. There is a high 
interest to uncover the underlying mechanisms of radiation-induced lung injury, especially 
fibrosis, due to its poor clinical prognosis. Therefore, the investigation of the role of CD73 
and adenosine in the model of RILF is of great importance. 
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1.4.3 Hyaluronan 
HA is another important modulator of lung homeostasis. As part of the ECM it 
influences lung elasticity, airway resistance and compliance [158]. HA is also called 
hyaluronic acid and composed of polymers from D-glucoronic acid and D-N-
acetylglucosamin linked via alternating ȕ-1,4 and ȕ-1,3 glycosidic bonds. It is a nonsulfated 
glycosaminoglycan and can be found in various tissues all over the human body. Unlike 
other glycosaminoglycans HA is not synthesized in the golgi, but three HA synthases (Has1-
3) produce HA molecules at the inner surface of the plasma membrane (Figure 4) [140]. 
While Has1 and Has2 synthesize high molecular weight (HMW) HA molecules, Has3 
produces HA chains of low molecular weight (LMW) [58, 155]. Every day approximately one 
third of the whole HA content is renewed, although it is known that ROS triggers an 
enhanced HA turnover [40, 133]. HA can be degraded to oligosaccharides by the enzymatic 
reaction of hyaluronidases (HYAL) [140]. In humans and mice six HYAL genes code for 
enzymes with distinct catalytic characteristics. Nevertheless, it is thought that HYAL1 and 
HYAL2 are the most abundant and active proteins [27]. 
Common HA receptors are CD44 and the receptor for HA-mediated motility 
(RHAMM). CD44 is expressed on hematopoietic cells, fibroblasts and various tumor cells. It 
is a cell surface glycoprotein and is known to be a HA receptor, while binding of HA to CD44 
is dependent on the activation state of the receptor [75]. HMW HA as well as LMW HA can 
Figure 4: Synthesis and degradation of HA. HA is synthesized by one of three different HA synthases (Has1-3) 
in the cell membrane. Has1 and Has2 produce HMW HA, whereas Has3 produces LMW HA molecules. 
Degradation of HA is initialized by HYAL2 on the plasma membrane with the help of CD44. HA is fragmented and 
internalized. Later on, in lysosomes, HYAL1 and the low pH will degrade HA in small fragments (Stridh 2012
[140]). 
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bind to CD44 [140]. Besides HA, CD44 is able to bind to proteins of the ECM as well as 
cytokines and chemokines and growth factors [106, 114]. RHAMM, which is also named 
CD168, can be found on the cell surface, in the nucleus and in the cytoplasm of a cell [88]. 
Surface RHAMM is GPI-anchored and plays an important role in cell motility as well as 
wound healing in interaction with CD44 [150]. 
In the healthy lung tissue HA is found in the basement membrane. Fibroblasts are the 
main producers of the ECM molecule HA, but HA is also produced and secreted by smooth 
muscle cells [115]. During tissue homeostasis HA exists as a HMW polymer with a size of 
more than 106 Dalton [92]. Inflammation causes a depolymerization of HMW HA, for example 
through oxygen radicals, leading to the formation of LMW HA fragments with a size around 
2x105 Dalton [107, 115]. The functions of the high and low molecular weight form of HA differ 
a lot. HMW HA is known to be a hydrating and structural polymer with anti-inflammatory 
capacities. LMW HA has pro-inflammatory effects, promotes proliferation, and acts in 
combination with specific receptors (CD44, RHAMM, TLRs) [104, 139, 145]. In response to 
IR HA polymers are fragmented to LMW HA, which function as an early danger signal, since 
they belong to the earlier mentioned DAMPs [133, 149]. DAMPs induce an immune response 
that needs to be regulated and controlled. Failure of immune regulation will contribute to a 
chronic inflammation and tissue fibrosis [116, 147]. 
1.4.4 Role of the hyaluronic system in pneumopathy 
It is suggested that impaired ECM function can lead to lung fibrosis and potentially 
loss of function [158]. It was shown that the levels of HA in BAL samples from IPF patients 
are elevated [10] and that HA is accumulating before fibrosis and prior to the influx of 
inflammatory cells [92]. BLM-induced lung injury in the rat also confirmed enhanced HA 
levels, and especially accumulation of LMW HA fragments, in the lung tissue as well as the 
BAL fluid [55]. Furthermore, HA seems to impact on TGFȕ-driven pro-fibrotic processes like 
the transition of primary human lung fibroblasts to myofibroblasts [93]. 
CD44 is a main contributor to HA clearance after lung injury and can thereby 
counteract chronic inflammatory stages and fibrosis development [170]. Furthermore, lung 
fibrosis is characterized by the abundance of myofibroblasts that express Has2 and are 
invasive. Vice versa the HA receptor CD44 was shown to be important to recruit fibroblasts 
and to contribute to the invasive phenotype of myofibroblasts [77]. The expression of the HA 
receptor RHAMM is also elevated upon BLM-induced lung tissue injury. RHAMM is essential 
in tissue repair processes and the interaction between HA and RHAMM is necessary for 
macrophage chemotaxis towards injured lungs [170]. The loss of RHAMM is associated with 
decreased levels of TGFȕ upon injury, thereby preventing a fibroblast into myofibroblast 
differentiation [147]. Macrophages seem to be the main cell type executing the observed 
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effects of LMW HA in response to lung tissue injury [107, 127]. Macrophages and HA co-
localize in the injured lung tissue upon i.t. BLM treatment in rats. The accumulation of 
macrophages in the injured lung was abolished by treatment with a HA-binding peptide 
mimicking the binding domain of RHAMM [127]. 
So far, not much research has been done to define a potential role the HA system in 
radiation-induced pneumopathy. In breast cancer patients that underwent RT, enhanced 
levels of HA were found in the BAL [9]. In a radiation-induced lung disease model in the rat 
also elevated levels of HA were found in the BAL, serum and lung tissue [123]. One murine 
based radiation-induced lung injury study with a single dose of 10 Gy reported enhanced 
levels of HA only at 12 hours after RT within an observation period up to 12 weeks [59]. 
Although HA is associated with different fibrotic diseases of the lung, its impact on RILF has 
been rarely studied so far. 
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2 Aim of the project 
Radiation-induced pneumonitis and pulmonary fibrosis are severe and dose-limiting 
side effects of thoracic irradiation for cancer treatment and of TBI in conditioning regimens 
for hematopoietic stem cell transplantation. To improve treatment outcome there is high 
interest in the development of new strategies to either sensitize the tumor tissue to the toxic 
effect of IR or to protect the normal tissue from the adverse radiation effects. However, the 
signaling molecules associated with infiltration/inflammation and the disease-promoting 
capabilities of diverse immune cells are still largely unknown. Therefore the identification of 
new biomarkers and therapeutic targets for prediction, prevention or treatment of radiation-
induced pneumonitis and fibrosis are important. 
In this context studies with preclinical rodent models and patient data identified a 
complex response of the lung tissue after RT with multiple interactions between resident lung 
cells and infiltrating immune cells. The role of the different types of immune cells during 
pneumopathy is still poorly defined. Previous work from our group using a murine model of 
radiation-induced pneumopathy revealed alterations in leukocyte-associated 
cytokines/chemokines as well as in immune cell recruitment (lymphocytes and myeloid cells) 
during radiation-induced pneumonitis [17]. Preclinical murine studies as well as patient 
studies suggested a contribution of lymphocytes and macrophages in fibrotic pulmonary 
diseases, but a potential contribution and underlying mechanism in radiation-induced lung 
injury remained unknown. Moreover, studies identified CD73 and/or adenosine as well as HA 
as important factors contributing to fibrosis development in other types of lung injury. 
Thus, the aim of my project was the detailed characterization of immune cells, 
especially macrophages, and the identification of the impact of CD73/adenosine and HA 
during radiation-induced lung damage using our murine in vivo model of radiation-induced 
pneumopathy. This project is of great importance to understand the disease progression and 
for the identification of promising candidates for prevention as well as the development of 
treatment options for counteracting disease-promoting immune changes. 
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3 Results 
3.1 Publication overview 
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Radiation-induced pneumonitis and pulmonary fibrosis are dose-limiting side effects 
of thoracic irradiation, but its pathogenesis remains poorly understood and no effective 
treatment is available. The following publications give new insights for a better understanding 
of the pathogenic processes and offer potential treatment approaches to reduce normal 
tissue toxicity in the lung. We used the murine model of radiation-induced pneumopathy and 
irradiated C57BL/6 wildtype mice with a single high dose of 15 Gy over their whole thorax to 
study radiation-induced pneumonitis and fibrosis. Since the infiltration of various immune 
cells is a common feature of pneumonitis and fibrosis, we analyzed T cells with a focus on 
Treg and macrophages in irradiated versus non-irradiated mice. Furthermore, there were 
hints from other types of pulmonary fibrosis that altered signaling pathways, e.g. purinergic 
and hyaluronic signaling, contribute to the microenvironmental changes observed during 
fibrosis. Therefore, we included CD73-/- mice in our studies of radiation-induced fibrosis and 
analyzed components of the hyaluronic signaling pathway. 
Thorax irradiation of C57BL/6 mice altered the composition of T cell populations 
locally and systemically (cervical lymph nodes and spleen). Lung irradiation led to increased 
levels of Treg and to upregulation of CD103, cytotoxic T-lymphocyte-associated protein4 
(CTLA-4) and CD73 on T cells at 3 weeks after IR. These markers are known to promote 
recruitment and immunosuppressive activity. At six and twelve weeks post irradiation 
(pneumonitic phase) an influx of CD3+ T cells was observed. In addition to an increased 
CD73 expression on T cells, CD73 expression and activity was also upregulated on other 
immune cells and non-leukocytes in the irradiated lung. Elevated levels of Treg were also 
found during the fibrotic phase. The upregulation of CD73 was paralleled by progressively 
accumulating levels of extracellular adenosine. CD73 deficient mice failed to accumulate 
adenosine in BALF and exhibited significantly less RILF. Furthermore, treatment of wild-type 
mice with pegylated ADA (PEG-ADA) or a CD73 antibody (TY/23) significantly reduced RILF. 
The development of RILF in WT mice was accompanied by the accumulation of 
macrophages within organized clusters expressing pro-fibrotic marker proteins such as 
TGFȕ, alpha smooth muscle actin (Į-SMA) and ARG1. Interestingly, in CD73-/- mice no 
organized macrophage clusters and no upregulation of anti-inflammatory markers on 
macrophages were observed during the fibrotic phase. Furthermore, CD73-/- mice showed a 
differential expression of the HA synthases and the receptors CD44 and RHAMM. 
In sum, the data reveal that immune cells of the innate and adaptive immune system 
as well as the purinergic and hyaluronic system impact on radiation-induced pneumonitis and 
fibrosis and suggest a cross-talk between the investigated components.  
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3.2 Thorax irradiation triggers a local and systemic accumulation 
of immunosuppressive CD4+ FoxP3+ regulatory T cells. 
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3.3 Extracellular adenosine production by ecto-5'-nucleotidase 
(CD73) enhances radiation-induced lung fibrosis. 
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o Analyses of flow cytometry data: Figure 2, 3D  
• RNA isolation and QPCR analyses Figure 4E, 5C+D, 6F  
o established method to isolate RNA from murine tissue samples with the 
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o primer design and optimization for QPCR 
o Performed QPCR for Figure 4E, 5D, 6F 
• Administration of PBS, PEG-ADA and TY/23 to mice for Figure 6 (with Wirsdörfer and 
Meyer) 
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3.4 Loss of CD73 prevents accumulation of alternatively activated 
macrophages and the formation of pre-fibrotic macrophage 
clusters in irradiated lungs  
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Abstract  
Alternatively activated macrophages play a pathogenic role in idiopathic pulmonary 
fibrosis but their contribution to radiation-induced lung fibrosis remains elusive. We 
aimed to define alterations in the numbers and phenotypes of total and alveolar 
macrophages (AM) upon whole thorax irradiation (WTI) and to explore a potential 
role of radiation-induced environmental lung changes for driving AM polarization in a 
murine model with a focus on CD73 and adenosine. For this, wild type C57BL/6 (WT) 
mice and CD73 knockout mice (CD73-/-) received a single dose whole thorax 
irradiation (15 Gray). Lung tissue was collected at defined time points post-irradiation 
for isolation and phenotyping of myeloid cells (monocytes/macrophages) and 
complementary histological, immunohistochemical and RNA analyses. We observed 
a dramatic loss of AM at 3 weeks post-irradiation in WT and CD73-/- mice. Myeloid 
cells repopulated the lung tissue of WT mice within 6 weeks after irradiation, whereas 
CD73-/- mice showed a trend to delayed macrophage repopulation. Total 
macrophages and AM displayed increased surface-expression of pro-inflammatory 
markers such as MHCII throughout the observation period in both strains but 
particularly in CD73-/- mice. In contrast, we detected a significant up-regulation of the 
anti-inflammatory macrophage mannose receptor 1 (MMR) during the fibrotic stage 
only on AM of WT mice. Interestingly, the development of radiation-induced 
pulmonary fibrosis in WT mice was accompanied by the accumulation of 
macrophages within organized clusters expressing pro-fibrotic marker proteins such 
as transforming growth factor beta (TGFβ), alpha-smooth muscle actin (α-SMA) and 
arginase-1 (ARG1). In contrast reduced fibrosis development in CD73-/- mice was 
associated with a failure to develop clusters of alternatively activated macrophages. 
We speculate that accumulation of alternatively activated macrophages in organized 
clusters represents the origin of fibrotic foci in the irradiated lung and is driven by the 
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cross-talk of chronic accumulation of adenosine, the hyaluronic acid system and 
potentially TGFβ.  
 
Introduction  
Radiation is a major treatment option for cancer patients. However, the normal 
lung tissue is highly sensitive to radiation-induced damage and has only little repair 
capacity. As a consequence, radiation-induced pneumonitis and pulmonary fibrosis 
may develop in patients upon thoracic or total body irradiation (TBI), thereby reducing 
survival rates and quality of life [1, 2]. So far no effective treatment is available for 
clinical use, so that these dose-limiting side effects are still a major barrier to 
successful radiotherapy of thorax-associated neoplasms [3, 4].  
Deregulated cytokine production without or with aseptic lung inflammation is a 
frequent pathologic finding in patients after thoracic irradiation or TBI [4, 5] and is 
observed in murine models [4, 6-10]. In own investigations, the time-dependent 
recruitment of immune cells to the lung tissue after hemithorax irradiation of C57BL/6 
mice with 15 Gray (Gy) was associated with a significant increase in the levels of 
various monocyte/macrophage associated cytokines and chemokines, for example 
macrophage-colony stimulating factor (M-CSF), macrophage chemoattractant 
protein-1 (MCP-1; CCL-2), macrophage inflammatory proteins (MIP)-1 and MIP-2 in 
the bronchoalveolar lavage fluid (BALF) of irradiated mice compared to sham 
controls [11].  
M-CSF and MCP-1 promote the influx, proliferation or differentiation of 
monocytes/macrophages and have been associated with increased macrophage 
accumulation, production of connective tissue growth factor (CTGF) and fibrosis in 
bleomycin-induced lung fibrosis [12]. A pathogenic role of macrophages has also 
been postulated for idiopathic pulmonary fibrosis (IPF) [13, 14]. The influx of myeloid 
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cells has also been observed in murine models of radiation-induced pneumopathy 
during both, the pneumonitic phase and the fibrotic phase [15-17]. Importantly, 
several reports including our own studies suggested a potential role of foamy 
macrophages or alternatively activated macrophages in radiation-induced adverse 
late effects though the responses may depend on the mouse strain [11, 16, 18-20].  
Generally, mononuclear phagocytes participate in orchestrating innate and 
adaptive immune responses and thereby play essential roles in inflammation and 
host defense against infections. But they also exert homeostatic functions in diverse 
tissues, coordinate tissue remodeling in injured tissues or within the tumor 
environment, and even impact host metabolism [21, 22]. Their high plasticity allows 
macrophages to adapt quickly to various environmental signals such as those from 
lymphocyte subsets or danger signals in injured tissues [23]. Macrophages have 
initially been classified into classically activated (M1) and alternatively activated (M2) 
populations executing predominantly pro-inflammatory or anti-inflammatory actions, 
respectively [24]. However, it is now clear that macrophages can adopt various 
phenotypes as a continuum in between the M1/M2 extremes, including mixed M1/M2 
phenotypes under pathological conditions [25], and that the various phenotypes have 
tissue- and context-dependent functions [26, 27].  
We recently showed that activation of ecto-5-nucleotidase (NT5E, CD73) and 
chronic accumulation of adenosine participate in radiation-induced lung fibrosis and 
that genetic deficiency or pharmacologic inhibition of CD73/adenosine signaling 
reduces extracellular adenosine thereby significantly decreasing radiation-induced 
fibrosis in mice [17]. CD73 and adenosine play critical roles in balancing tissue 
inflammation and repair processes regulating, amongst others, leukocyte 
extravasation and function [28-32]. But depending on the disease model (acute or 
chronic) extracellular accumulation of adenosine has either tissue protective or 
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adverse effects in pulmonary fibrosis [17, 33-35].  
Fibrosis is characterized by excessive deposition of extracellular matrix (ECM) 
molecules [36]. These include mainly collagens and fibronectin but the 
glycosaminoglycan hyaluronan (hyaluronic acid, HA) can also participates in the 
regulation of chronic lung inflammation and fibrosis, at least in the preclinical 
bleomycin model [37-39]. Cell stress triggers the fragmentation of high molecular 
weight (HMW) HA to low molecular weight (LMW) HA and interactions between LMW 
HA and macrophages [38, 40, 41], as well as between the HA system and adenosine 
signaling through two (ADORA2A, ADORA2B) of its four receptors are well 
documented [39, 42]. Our own previous work revealed that HA accumulates in 
murine lungs during the fibrotic phase [43]. However, not much is known about the 
regulation of macrophage phenotype and functions in the changing environment of 
irradiated lungs and their impact on the development of radiation-induced lung 
fibrosis. Here, we aimed to gain further insight into radiation-induced immune 
changes in the lung tissue. In particular, we aimed to characterize radiation-induced 
changes in macrophage recruitment, differentiation and function, and to define their 
role for fibrosis development in a murine model with a focus on suspected regulatory 
molecules identified in our previous work such as adenosine as well as HA.  
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Materials and Methods 
Mice 
C57BL/6 wild-type (WT; CD73+/+; Harlan) and CD73-/- mice (C57BL/6 
background) [29] were bred and housed under specific pathogen-free conditions in 
the Laboratory Animal Facilities of the University Hospital Essen. Food and drinking 
water were provided ad libitum. The animal facility and all protocols were approved 
by the Universities Animal Protection Boards in conjunction with the Landesamt für 
Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen (LANUV) according to 
the German animal welfare regulations (AZ.8.87-51.04.20.09.333, AZ.84-
02.04.2011.A407). 
 
Irradiation 
Mice (8-12 weeks) were anesthetized with 3% isoflurane and irradiated in 
0.8% isoflurane with either a single dose of 0 Gy (sham control) or with 15 Gy over 
their whole thorax (WTI) using a Cobalt-60 source (Philips, Hamburg, Germany) [44]. 
Mice were sacrificed at 3, 6, 12, 24, or 25-30 weeks post-irradiation and lung tissue 
was collected.  
 
Lung leukocyte phenotyping 
Total lung cells were isolated as described previously [44]. Isolated cells were 
stained with anti-mouse CD45 PacificBlue (30-F11) for total leukocytes. Within lung 
leukocytes, myeloid cells were defined with anti-CD11b PerCP-Cy5.5 (M1/70), 
macrophages were defined with anti-F4/80 PE-Cy7 (BM8), and AMs were defined 
with anti-CD11c BV (N418) and increased FL-1 autofluorescence as recently 
published [45]. Populations were further characterized with anti-MHCII APC 
(M5/114.15.2) and anti-MMR PE (C068C2). Antibodies were obtained from BD 
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Biosciences (Heidelberg, Germany), BioLegend (Fell, Germany) or eBioscience 
(Frankfurt, Germany). Data acquisition and analysis were performed on a LSRII 
using FACS DIVA (BD Bioscience, USA) and FlowJo (Tree Star, Ashland, USA). 
 
RNA isolation 
Tissue RNA: Fresh frozen lung tissue was pulverized, lysed in RLT buffer 
(Qiagen, Hilden, Germany) and sonicated with an Ultraturrax IKA T10 (IKA, Staufen, 
Germany) for 30 seconds. RNA was further isolated using the homogenizer 
QIAshredder and RNeasy Mini Kits (Qiagen) according to the manufacturer’s 
instructions. 
 
Quantitative real-time PCR (QPCR) 
RNA was reversely transcribed with the QuantiTect Reverse Transcription Kit 
(Qiagen). QPCR expression levels were normalized to the reference gene (-actin; 
set as 1). Quantitative real-time PCR was carried out using specific oligonucleotide 
primers (-Actin (Actb): fw, CCAGAGCAAGAGAGGTATCC; rev, 
CTGTGGTGGTGAAGCTGTAG; iNOS (Nos2): fw, AGCTCCTCCCAGGACCACAC; 
rev, ACGCTGAGTACCTCATTGGC; ARG1 (Arg1): fw, 
GTGAAGAACCCACGGTCTGT; rev, CTCGCAAGCCAATGTACACG; IL-10R 
(Il10ra): fw, AGGCAGAGGCAGCAGGCCCAGCAGAATG; rev, 
TGGAGCCTGGCTAGCTGGTCACAGTAGG; Has3 (Has3): fw, 
GATGTCCAAATCCTCAACAAG; rev, CCCACTAATACATTGCACAC; CD44 (Cd44): 
fw, AGGATGACTCCTTCTTTATCCG; rev, CTTGAGTGTCCAGCTAATTCG; 
RHAMM (Hmmr): fw, GAATATGAGAGCTCTAAGCCTG; rev
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CCATCATACTCCTCATCTTTGTC, using QPCR MasterMix for SYBR® Assay ROX 
(Eurogentec, Cologne, Germany) according to the manufacturer’s instructions. 
 
Histopathology 
Paraffin embedded tissue: Lungs were perfused (with PBS) and then fixed 
overnight with 4% (wt/vol) paraformaldehyde in PBS (pH 7.2). Upon dehydration, 
lungs were embedded in paraffin and sectioned into 5 µm slices.  
Immunohistochemistry: 
iNOS (NOS2), ARG1 (ARG1) TGF- (TGFB1), -SMA (ACTA2): 
Immunohistochemical (IHC) staining of paraffin-embedded lung tissue slides was 
performed using the Mouse on Mouse (M.O.M.™) ImmPRESS™ HRP (horseradish 
peroxidase) Polymer Kit (Vector Laboratories, Burlingame, USA) according to the 
manufacturer’s instructions. Anti-inducible nitric oxid synthase (iNOS) (BD 
Biosciences, Heidelberg, Germany), anti-ARG1 (Santa Cruz Biotechnology, 
Heidelberg, Germany), anti-TGF (R&D Systems, Wiesbaden, Germany) and anti--
SMA (Merck Millipore, Darmstadt, Germany) were used as mouse primary 
antibodies. The ImmPACT™ VIP Peroxidase (HRP) Substrate Kit (Vector 
Laboratories) was used to detect TGF and -SMA according to the manufacturer’s 
instructions. Stained sections were counterstained with hematoxylin. 
Mac-3 (LAMP2): Tissue slides were deparaffinised, rehydrated and steam 
boiled in citrate buffer pH 6. After blocking endogenous peroxidase with 3% H2O2, 
sections were blocked for 20 min with 2% normal goat serum (NGS) and 
subsequently incubated with anti-Mac-3 antibody (BioLegend, Fell, Germany) 
overnight at 4°C. Mac-3 was detected by secondary antibody linked to HRP and 
subsequent Diaminobenzidine (DAB) staining. 
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Affinity histochemistry: 
bHABP (HA binding protein): Tissue slides were deparaffinised, rehydrated 
and endogenous peroxidase activity was blocked with 3% H2O2. Affinity 
histochemistry of HA was performed incubating biotinylated bHABP overnight (ON) 
(Seikagaku, Tokyo, Japan) and further detection using HRP-labeled streptavidin 
(Calbiochem, Bad Soden, Germany) and subsequent DAB staining.  
 
Immunofluorescence: 
ARG1/Mac-3 double staining: Immunofluorescence staining of paraffin-
embedded lung tissue slides was performed using the Mouse on Mouse (M.O.M.™) 
Immunodetection Kit BASIC (Vector Laboratories) according to the manufacturer’s 
instructions. Tissue sections were incubated with anti-ARG1 antibodies ON at 4°C. 
Anti-ARG1 was detected using Alexa Fluor® 555 conjugate (Invitrogen, Thermo 
Fisher Scientific, Waltham, USA). Slides were the blocked with 2% NGS and 
incubated with anti-Mac-3 antibody ON at 4°C. Anti-Mac-3 was detected using Alexa 
Fluor® 488 conjugate (Invitrogen). 
 
Statistics 
Statistical analyses were performed using Prism 5.0 (GraphPad). For 
normalization, sham control values were set to 100% or 1 and values for irradiated 
animals were depicted as % of sham controls or relative to controls. Student’s two-
tailed unpaired t tests were used to compare differences between two groups. Two-
way ANOVA with post-hoc Sidak’s multiple comparisons test was used to compare 
groups split on two independent variables. Statistical significance was set at P <0.05. 
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Results 
Thorax irradiation triggers an early loss of pulmonary macrophages, influx of 
CD11b+ cells, and upregulation of pro- and anti-inflammatory macrophage 
markers 
To study the macrophage response in irradiated lungs, we exposed mice to WTI with 
a single dose of 15 Gy or 0 Gy (sham control) and dissected the lung tissue for flow 
cytometric analysis at different time-points. Total macrophages were gated based on 
CD45 and F4/80 staining (Fig. 1A upper panel). In non-irradiated mice the proportion 
of F4/80+ pulmonary macrophages from leukocytes (CD45+) was 20.9±0.6%. 
Irradiation led to a significant reduction in the percentage of F4/80+ macrophages at 3 
weeks after IR (Fig 1B). We identified AM among living leukocytes by a gating 
strategy recently developed by Vermaelen and colleagues for distinguishing AM 
(CD45+CD11chigh autofluorescent cells) from pulmonary dendritic cells [45]. This 
strategy is depicted in Fig. 1A middle panel and revealed a percentage of AMs in 
total living CD45+ leukocytes in control mice of 6.8±0.6% (Fig. 1A). Exposure to 
ionizing radiation (IR) caused a reduction in AM levels of almost 90% after 3 weeks 
(Fig. 1C) and was accompanied by significantly enhanced levels of CD11b+ 
monocytic cells within the leukocyte population (Fig. 1A lower panel + 1D). The level 
of CD45+CD11b+ cells in non-irradiated mice was on average 36.2 ±1.1%.  
To analyze the phenotype of macrophages we used major histocompatibility complex 
II (MHCII) as marker for a pro-inflammatory phenotype and macrophage mannose 
receptor (MMR) as marker for alternative activation, respectively. Fig. 2A shows the 
strategy for determination of the mean fluorescence intensity (MFI) for MHCII and 
MMR on F4/80+ macrophages as well as AM. The flow cytometric analyses revealed 
that macrophages present in irradiated lung tissue 3 weeks after IR express MHCII 
and MMR (Fig. 2B).  

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When analyzing the proportions of macrophages and CD11b+ cells at different time 
points after IR, percentages of macrophages recovered at 6 weeks upon radiation 
treatment compared to non-irradiated controls with a trend for a slight delay in 
complete recovery of AM (Fig. 2C). 
 
Pulmonary macrophages undergo changes in their phenotype during the 
fibrotic stage 
We next investigated time-dependent changes in the macrophage phenotype in 
fibrosis-prone WT mice after irradiation. Flow cytometric analyses revealed a trend to 
enhanced levels of the pro-inflammatory marker MHCII throughout the observation 
period in the F4/80+ population whereas the anti-inflammatory marker MMR was 
found to be slightly but significantly enhanced only at 6 weeks after IR (Fig. 3A). AM 
also showed enhanced expression of MHCII throughout the observation period with a 
significant increase during the fibrotic phase at 25-30 weeks post irradiation (Fig. 3B). 
In contrast to F4/80+ macrophages we detected a significant up-regulation of MMR 
expression on AM at 25-30 weeks after IR.  
 
Alternatively activated macrophages form clusters in the lung tissue and 
express pro-fibrotic markers 
Our earlier work revealed that histologic signs of fibrosis can be detected at 25-30 
weeks after IR [17, 43]. We therefore performed a detailed immunohistochemical 
analysis of macrophages for this time-point and found that macrophages 
accumulating in the lung tissue during the fibrotic phase formed organized clusters 
(Fig. 4A) and showed pronounced expression of ARG1, a marker for alternatively 
activated macrophages [18], and of the pro-fibrotic markers TGF and -SMA (Fig. 
4B+C), respectively. In contrast, expression of the pro-inflammatory iNOS could be 
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detected in only a few clusters. Double staining of tissue sections with Mac-3 and 
ARG1 confirmed a specific co-localization of ARG1 on macrophages (Fig. 4B). 
QPCR analyses of whole lung tissue RNA samples from 12 and 25-30 weeks after IR 
confirmed the enhanced expression of ARG1, whereas iNOS and the receptor of 
interleukin 10 (subunit alpha) (IL-10R) showed slightly enhanced but not 
significantly different values (Fig. 4D). 
 
CD73 deficiency prevents the accumulation of alternatively activated 
macrophages  
 Our previous work revealed that genetic deficiency of ecto-5'-nucleotidase 
(CD73) attenuates radiation-induced pulmonary fibrosis in CD73-/- mice [17]. We 
were therefore interested in whether loss of CD73 would affect accumulation and 
phenotype of pulmonary macrophages. Indeed, genetic loss of CD73 was associated 
with a failure of pulmonary macrophages to develop organized macrophage clusters 
at 25-30 weeks post-IR (Fig. 5A). 
 Furthermore, comparable to the results obtained in WT mice we found that 
F4/80+ lung macrophages isolated from irradiated CD73-/- mice displayed up-
regulated expression of the pro-inflammatory marker MHCII throughout the 
observation period (Fig. 5B left panel) whereas the anti-inflammatory marker MMR 
was not enhanced at any time point (Fig. 5B right panel). MHCII was also 
significantly up-regulated on CD73-/- AM at 3 and 25-30 weeks after irradiation (Fig. 
5C left panel). However, in contrast to the observations in WT mice MMR was found 
to be up-regulated on CD73-/- AM only at the 3 weeks time but not during the fibrotic 
phase (Fig. 5C right panel). QPCR analyses from whole lung tissue RNA samples 
(Fig. 5D) revealed that neither ARG1 nor IL-10Rα or iNOS were enhanced in CD73 
deficient mice upon IR, confirming the failure to initiate alternative activation in 
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macrophages. Taken together the results suggest that the pathogenesis of radiation-
induced lung fibrosis involves an accumulation of AM in organized clusters and a 
CD73-dependent shift of these AM towards an alternatively activated phenotype. 
 
CD73 deficiency impacts on the HA signaling pathway 
 Earlier reports pointed to a link between the HA system and adenosine 
signaling [39, 42]. Furthermore, our previous work revealed increased deposition of 
HA in WT mice during the fibrotic phase [43]. Affinity histochemical staining for HA 
binding protein (HABP) corroborated the accumulation of HA within the fibrotic areas 
(Fig. 6A). A detailed analysis of the time course of HA accumulation revealed that HA 
deposition became visible already at 16-20 weeks (Fig. 6A). Interestingly, HA 
staining seemed to be more diffuse at the late time-point (30 weeks). Of note, no 
histologically detectable formation of HA positive fibrotic foci could be observed in the 
CD73-/- mice (Fig. 6A right panels). 
 Next we examined whether the time-dependent changes in HA abundance in 
irradiated lungs of WT mice and the differences between WT and CD73-/- mice could 
be attributed to radiation-induced differences in the regulation of genes of the HA 
pathway (Fig. 6B and C). For this we compared relative mRNA expression levels of 
irradiated whole lung tissue samples and sham controls from WT and CD73-/- mice. 
Has1 and Has2 underwent reciprocal changes in expression after IR in both, WT and 
CD73-/- animals (Fig. 6B). While Has1 levels declined over time until the fibrotic 
phase Has2 underwent a time-dependent up-regulation after irradiation with highest 
levels observed in the fibrotic phase. Interestingly, at the 12 week time-point and thus 
just before the onset of visible HA deposition in WT mice, Has1 and Has2 expression 
was increased in WT compared to CD73-/- mice (Fig. 6B).  
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 Instead, Has3 was found to be up-regulated at the 3 week time point in the 
lungs of irradiated WT animals and declined throughout the observation period; in 
contrast, in CD73-/- mice Has3 expression was low at the 3 week time point but 
showed a significant increase during the fibrotic phase (Fig. 6C). This was paralleled 
by a comparable time-course in the expression of the HA receptors CD44 and 
hyaluronan-mediated motility receptor (Hmmr, RHAMM) in CD73-/- mice (Fig 6C). In 
contrast, the expression of CD44 remained almost unchanged in WT mice whereas 
the expression of RHAMM displayed a dual increase at the 3 week and the 30 week 
time-points in these mice, respectively (Fig 6C). 
  
	
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Discussion 
 Here we demonstrate for the first time that thorax-irradiation of fibrosis-prone 
C57BL/6 mice triggers a switch of AM towards an alternatively activated phenotype 
and their accumulation in organized clusters expressing fibrotic marker proteins 
during the fibrotic phase. Genetic deficiency of CD73 abrogated both, the phenotypic 
switch of AM and the formation of organized macrophage clusters in the irradiated 
lung tissue. Reduced deposition of ECM molecules in CD73-/- mice was accompanied 
by specific differences in the expression of genes of the HA system and reduced HA 
deposition. We conclude that radiation-induced activation of the CD73/adenosine and 
HA pathways cooperate in promoting radiation-induced pulmonary fibrosis by driving 
the formation of macrophage clusters and a phenotypic switch of AM towards 
alternatively activated, pro-fibrotic phenotypes in the context of further radiation-
induced changes in the pulmonary environment. 
 In detail, while the percentage of pulmonary macrophages, particularly AMs, 
declined during the first weeks after WTI, which is consistent with findings by others 
[20], we detected an increased influx of CD11b+ myeloid cells. As this myeloid cell 
population is known to contain macrophage precursors we speculate that radiation-
induced tissue damage and subsequent up-regulation of monocyte-chemoattractants 
trigger the influx of myeloid cells into the lung tissue to replace eradicated tissue 
resident macrophages [11, 46]. Accordingly, we observed a reconstitution of F4/80+ 
macrophages at 6 weeks and of AMs at 12 weeks post-irradiation that was 
accompanied by a normalization of CD11b+ cell levels. In line with our observations, 
bone-marrow-derived cells replaced eradicated AMs in unshielded murine lungs 
around 6 weeks after TBI [47] whereas under homeostatic conditions AMs expand 
via self-renewal [48]. 
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 Macrophage-phenotyping in WT mice revealed that pro-inflammatory markers 
like MHCII were significantly up-regulated in F4/80+ macrophages and in remaining 
AM at the 3 week time-point. The anti-inflammatory marker MMR was also 
significantly up-regulated at early time points on F4/80+ macrophages (6 weeks post-
irradiation) and AMs (3 weeks post-irradiation). While MHCII levels remained 
elevated during the observation period in both macrophage populations, expression 
levels of MMR declined during the transition phase but were up-regulated during the 
fibrotic phase specifically on AM. Our findings corroborate earlier reports on the 
generation of alternatively activated macrophages in murine lungs upon thoracic 
irradiation [18, 20], though the murine studies differ in radiation doses, investigated 
time points, as well as markers and gating-strategies used to identify pulmonary 
macrophages. A contribution of alternatively activated macrophages to bleomycine-
induced lung fibrosis in mice has also been suggested [49].  
 The generation of alternatively activated macrophages in irradiated lungs was 
associated with their accumulation in organized clusters. This is reminiscent of 
findings in the rat model of bleomycin-induced pulmonary fibrosis where organized 
macrophage clusters were observed at day 7 and 14 after intratracheal bleomycin 
injection [50]. Furthermore, focal lesions containing numerous macrophages were 
observed in lungs of irradiated C57L/J mice, but already at 8 weeks post-irradiation 
[51]. A strong association between organized macrophage clusters in the lung and 
fibrosis development was also reported in a model of targeted type II alveolar 
epithelial cell injury [52]. Instead, Franko and coworkers described the formation of 
focal lesions containing TGFβ positive fibroblasts upon single dose thoracic 
irradiation (15 Gy) in fibrosis-prone C57BL/6 mice but not in fibrosis-resistant 
C3HeB/FeJ mice [53]. In the present study we now demonstrate that organized 
macrophage clusters are exclusively present during the fibrotic phase and strongly 
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express pro-fibrotic mediators, suggesting a role for cluster-forming alternatively 
activated macrophages, presumably AMs, in radiation-induced pulmonary fibrosis. 
 So far, the role of macrophages in radiation-induced pneumopathy and the 
molecular networks involved in their regulation remained elusive. Here we show for 
the first time that in irradiated CD73-/- mice, macrophages fail to organize into clusters 
and AMs do not up-regulate markers for alternative activation such as MMR and 
ARG1. Our findings suggest a role for chronic CD73-dependent adenosine 
accumulation in driving the phenotypic switch in macrophages and a potential 
contribution of these alternatively activated alveolar macrophages in promoting 
radiation-induced fibrosis. This assumption is supported by earlier reports 
demonstratinga role of adenosine in driving and modulating alternative activation of 
macrophages [54-57]. Moreover, adenosine signaling has also been identified as 
contributor to fibrotic disease in other murine models in a tissue-dependent and 
injury-dependent manner [33, 58]. In this context, signaling via ADORA2B and 
ADORA3 seem to be particularly important in pulmonary fibrotic disease [14, 39, 59]. 
 Suggested mechanisms of the pro-fibrotic actions of pulmonary macrophages 
involve overproduction of reactive oxygen species as well as generation and 
activation of pro-fibrotic cytokines such as TGF [24, 60]. Comparative transcriptome 
analysis of lung tissue from fibrosis-prone and fibrosis-resistant mice exposed to 
thoracic irradiation revealed differences in the expression of signaling molecules 
associated with immune activation [61, 62]. Accordingly, we observed up-regulated 
mRNA and protein levels of TGF and osteopontin (OPN) upon WTI only in the lung 
tissue of C57BL/6 mice whereas the levels of these clinically relevant fibrotic markers 
were lower in the lungs of CD73-/- mice [17]. As the pro-fibrotic mediator TGF can 
induce alternative macrophage activation [63, 64] we speculate that the accumulation 
of TGF in irradiated lungs may cooperate with adenosine in driving the phenotypic 
		
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switch in macrophages during the fibrotic phase. Furthermore, macrophages can 
produce OPN induced downstream of ADORA2B signaling [65].  
 Interestingly, the specific knockout of ADORA2B on myeloid cells (LysMCre) 
reduced adenosine levels in the BALF, the numbers of alternatively activated 
macrophages and of -SMA+ fibroblasts, and fibrosis development in the chronic 
bleomycin model [14]. Moreover, CD73 and ADORA2B were up-regulated in lung 
biopsies from patients with chronic obstructive pulmonary disease (COPD) Stage 4 
or severe IPF, respectively, with their expression particularly confined to alternatively 
activated pulmonary macrophages [49]. These findings highlight a role of CD73-
activation, adenosine accumulation, and ADORA2B activation in driving the 
accumulation of alternatively activated macrophages and fibrotic pulmonary disease 
also in patients.  
 We also identified the HA pathway as another important modulator of 
radiation-induced pulmonary fibrosis, presumably through an interaction with the 
CD73/adenosine-pathway: We observed increased HA-deposition only in irradiated 
WT but not in CD73-/- mice. Furthermore, HA-deposition in WT lungs was observed 
at 16-20 weeks post-irradiation, and thus in parallel to the chronic accumulation of 
adenosine but prior to the occurrence of histologically detectable fibrosis described in 
our recent study [17]. Interestingly, the differences in HA deposition between 
irradiated WT and CD73-/- mice were associated with differences in the expression of 
HA synthases. At the critical 12 week time-point that represents the onset of 
adenosine accumulation [17] Has1 and Has2 displayed increased expression in WT 
compared to CD73-/- mice. These observations corroborate the suggested link 
between the adenosine and hyaluronan pathways in regulating tissue inflammation 
and fibrosis in other murine models and for patients with COPD [39, 42, 66]. In 
contrast, Has3 was up-regulated during the fibrotic phase only in the CD73-/- mice. 
	

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Unlike Has1 and Has2, Has3 mainly synthesizes LMW HA with reported pro-
inflammatory actions [67, 68]. Activation of the pro-inflammatory arm of the HA 
pathway during the fibrotic phase may thus help the CD73-/- mice to limit fibrosis 
development, e.g. through activating ECM-degrading enzymes [69].  
Taken together our results point to a pathogenic role of the accumulation of 
alternatively activated macrophages in pre-fibrotic clusters in radiation-induced lung 
fibrosis. Reduced extracellular adenosine accumulation in CD73-/- mice prevented 
macrophage from accumulation in organized clusters, to undergo a phenotypic 
switch, and to express pro-fibrotic markers in irradiated lungs. Thus, radiation-
induced increases in adenosine, TGF, and HA may cooperate in driving 
macrophage recruitment, activation and organization in pre-fibrotic clusters and 
fibrosis progression. Our findings contribute to a better understanding of the signaling 
networks driving polarized macrophage activation and fibrosis in the irradiated lung 
and may allow us to define new diagnostic biomarkers and therapeutic strategies for 
this dose-limiting adverse effect of thorax irradiation. 
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Figures and Figure Legends 
Figure 1 
 
Radiation treatment triggers early loss of pulmonary macrophages and an early 
influx of CD11b+ cells. C57BL/6 WT mice received 0 or 15 Gy WTI and were 
sacrificed at 3 weeks post-irradiation. Whole lung cells were stained and further 
analyzed by flow cytometry. (A) Gating strategy for F4/80+ macrophages, alveolar 
macrophages (AM, via the expression of CD11c and autofluorescent property of AM 
[45]) and CD11b+ cells from all living CD45+ cells in the lung, shown for a 0 Gy 



irradiated sample. Relative percentages of F4/80+ cells (B), AM (C) and CD11b+ cells 
(D) normalized to non-irradiated controls (n = 7). Shown are mean values ± SEM (B, 
C, D), **P  0.01, ****P  0.0001 by unpaired two-tailed t-test. 
 
Figure 2 
 
Whole thorax irradiation leads to upregulation of pro- and anti-inflammatory 
markers predominantly in alveolar macrophages. C57BL/6 WT mice received 0 
or 15 Gy WTI and were sacrificed at the indicated time points upon irradiation. Whole 
lung cells were stained and further analyzed by flow cytometry. (A) Histograms show 
representative samples (isotype control in light blue, 0 Gy in light grey and 15 Gy 
dark grey) for the surface markers major histocompatibility complex (MHCII) and 
macrophage mannose receptor (MMR) for F4/80+ macrophages (3 week time point) 
and AM (30 week time point). Indicated area was used for quantification. (B) At 3 
weeks post-irradiation, lung macrophages (F4/80+ macrophages or AM) were 
characterized for their expression of MHCII or MMR. Shown are mean fluorescent 



intensities (MFI) per cell (n = 7). (C) At the indicated time points leukocytes (CD45+) 
were stained with F4/80, CD11c or CD11b to define percentages of lung 
macrophages (n = 6/7, 6/6, 6/5, and 8/2 at the indicated time points), AMs (n = 6/7, 
6/6, 6/5 and 11/8 at the indicated time points) or monocytic cells (n= 6/7, 6/6, 6/6 and 
8/2 at the indicated time points) respectively. Shown are mean values ± SEM, *P  
0.05, ****P  0.0001 by unpaired two-tailed t-test (B) or by two-way ANOVA followed 
by Sidak’s multiple comparisons test (C). 
 
Figure 3 
 

	

Macrophages in the irradiated lung tissue undergo changes in their phenotype 
in the fibrotic state. C57BL/6 WT mice received 0 or 15 Gy WTI and were sacrificed 
at the indicated time points after irradiation. Bar diagrams (A) show the relative MFI 
of MHCII and MMR for F4/80+ macrophages (n = 6/7, 6/6, 6/5 and 8/2 at the 
indicated time points) or AMs (B, n = 6/7, 6/6, 6/5 and 12/6 at the indicated time 
points) at the indicated time points. Shown are mean values ± SEM, *P  0.05, ***P  
0.001, ****P  0.0001 by two-way ANOVA followed by Sidak’s multiple comparisons 
test. 
 
Figure 4 
 
Alternatively activated macrophages form clusters in the lung tissue and have 
a pro-fibrotic phenotype. C57BL/6 WT mice received 0 or 15 Gy WTI and were 
sacrificed at 25-30 weeks upon irradiation. (A) IHC staining of paraffin-embedded 
lung tissue with primary antibody for Mac-3 was performed to identify macrophages 




and macrophage clusters per section. Scale bar = 100µm. Numbers of clusters are 
shown in scatter plot (horizontal line indicates median). (B) Representative IHC 
pictures (from 15 Gy irradiated samples) for macrophage clusters stained with iNOS, 
ARG1, TGF or -SMA primary antibody are shown (left panels). Scale bar = 100µm. 
The right panels show an immunofluorescence double staining for Mac-3 and ARG1. 
Double staining results in a yellow signal. Scale bar = 100 µm. (C) Quantification of 
evaluated macrophage clusters from IHC stainings for indicated markers in scatter 
plots (horizontal line indicates median). (D) QPCR analysis for iNOS (n = 8/7 and 8/7 
at the indicated time points), ARG1 (n = 8/8 and 7/7 at the indicated time points) and 
IL-10R (n = 8/8 and 8/8 for both time points) from whole tissue RNA samples for 
indicated time points after irradiation, shown are mean values ± SEM. *P  0.05, **P 
 0.01, by unpaired two-tailed t-test (A+C) or by two-way ANOVA followed by Sidak’s 
multiple comparisons test (D). 
 
Figure 5 
 


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CD73 deficiency prevents the accumulation of alternatively activated 
macrophages. CD73-/- mice received 0 or 15 Gy WTI and were sacrificed at 
indicated time points. (A) IHC staining of paraffin-embedded lung tissue with primary 
antibody for Mac-3 was performed and macrophage clusters per section were 
counted. Numbers of clusters are shown in scatter plot (horizontal line indicates 
median). Bar diagrams show the relative MFI of MHCII and MMR for F4/80+ 
macrophages (B, n = 7/7, 7/7, 6/5, 6/6 and 7/3 at the indicated time points) or AMs 
(C, n = 7/7, 6/7, 6/5, 6/6 and 10/7 at the indicated time points) at indicated time 
points. (D) QPCR analysis for iNOS (n = 9/10 and 10/10), ARG1 (n = 9/10 and 10/10) 
and IL-10R (n = 10/9 and 10/10 at the indicated time points) from whole tissue RNA 
samples for indicated time points upon irradiation. Shown are mean values ± SEM, 
**P  0.01, ***P  0.001, by unpaired two-tailed t-test (A) or by two-way ANOVA 
followed by Sidak’s multiple comparisons test (B-D). 
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Figure 6 
 
RT induced pattern of hyaluronic signaling induction varies between WT and 
CD73-/- mice. C57BL/6 or CD73-/- mice received 0 or 15 Gy WTI and were sacrificed 
at indicated time points and lung tissue was dissected. (A) Shown are representative 
IHC stainings with hyaluronan binding protein (HABP) of 0 Gy or 15 Gy irradiated WT 
and CD73 knockout animals at the indicated time points. (B) QPCR analyses for 
Has1 and Has2 from whole tissue RNA samples at the indicated time points after 
irradiation. Shown are 2 technical replicates from pooled samples per time point as 
values from 15 Gy value compared to 0 Gy value (shown as mean ± SD). (C) 
QPCR analyses for Has3 (n = 10/9/6/6; 7/8/9/10; 7/8/10/10), CD44 (n = 10/9/6/6; 
7/7/8/10; 8/8/10/10) and RHAMM (n = 10/9/6/6; 7/8/9/10; 8/8/10/10) from whole 
tissue RNA samples at the indicated time points after irradiation (shown as mean ± 


SEM)). *P  0.05, **P  0.01, ***P  0.001, ****P  0.0001, by two-way ANOVA 
followed by Sidak’s multiple comparisons test. 
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4 Discussion 
In the present PhD project, new findings on the contribution of innate and adaptive 
immune cells as well as the purinergic and hyaluronic system to radiation-induced 
pneumopathy in a murine model have been revealed. Irradiation of the thoracic region in 
C57BL/6 wildtype mice led to an initial reduction of CD3+ T cells in the lung as well as in the 
spleen and cervical lymph nodes of the treated animals. While the levels of CD3+ T cells 
stayed reduced in spleen and lymph nodes, CD3+ as well as CD4+ T cell populations were 
increased in the lung at 6 and 12 weeks post RT. Furthermore, our data showed for the first 
time enhanced levels of immunosuppressive regulatory CD4+FoxP3+ T cells (Treg) at 3 and 
25-30 weeks after IR. 
Enhanced expression of CD73 was not only found on T cells but also on alveolar 
macrophages and CD45- cells within the lung tissue beyond the pneumonitic phase up to 30 
weeks post IR. We showed for the first time, that the enzymatic product of CD73, adenosine, 
accumulates in BAL as of week 16 in irradiated mice. Between 25 and 30 weeks after WTI, 
the pro-fibrotic mediators OPN and TGF were elevated and pronounced fibrosis was visible 
in the lung tissue. Interestingly, genetically (use of CD73-/- mice) or pharmacological targeting 
(with the monoclonal CD73 antibody TY/23) of CD73 or its product adenosine (with PEG-
ADA) resulted in reduced levels of BAL adenosine, reduced expression of OPN and TGF, 
and attenuated fibrosis development. 
Another difference we observed between wildtype and CD73-/- mice upon irradiation 
was the formation of organized macrophage clusters in the fibrotic tissue, which was 
restricted to wildtype animals. The formation of organized macrophage clusters in a murine 
model of RILF was described for the first time in the present project. Characterization of the 
macrophages from wildtype mice by flow cytometric and histologic approaches showed 
enhanced expression of anti-inflammatory markers on alveolar macrophages. These cells 
are presumably also the ones organized in clusters in the fibrotic lung tissue. In contrast, the 
macrophages from CD73-/- mice failed to express anti-inflammatory markers during the 
fibrotic phase, suggesting a connection between chronic enhanced levels of adenosine, the 
upregulation of anti-inflammatory markers on alveolar macrophages, the formation of 
organized macrophage clusters and fibrosis development. 
The hyaluronic system was identified as an additional potential contributor to RILF 
that was differentially regulated after irradiation of the whole thorax in CD73 wildtype and 
knockout mice. 
In the following, the findings of the project will be discussed in detail in the context of 
newest research findings and conclusions regarding the underlying mechanisms of radiation-
induced pneumopathy will be drawn. 
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4.1 The role of CD73 and adenosine 
The purinergic signaling plays an important role in the orchestration of inflammation 
and repair in the lung. CD39 and CD73 as well as their receptors are expressed on various 
pulmonary cells including cells of the innate and adaptive immune system [33]. In response 
to WTI, we found that CD73 was elevated on Treg and alveolar macrophages but also on 
other cells of leukocyte and non-leukocyte origin. The expression and activity of CD73 in the 
lung tissue raised time-dependently upon irradiation and led to high levels of extracellular 
adenosine measured in the BAL fluid. Enhanced CD73 activity and high extracellular 
adenosine concentrations were also observed in patients with asthma, COPD and IPF and 
could also been shown for BLM-induced lung injury (i.t.) [67, 152]. After WTI, adenosine was 
accumulating in the lung tissue before the detection of fibrotic lesions and foci, suggesting 
that high extracellular adenosine levels triggers fibrosis development.  
To prove the functional relevance of adenosine in our model we performed the 
experiments also in CD73 deficient mice. In our chronic lung injury model the loss of 
CD73/adenosine during the initial damage response upon lung injury protected mice from 
RT-induced barrier dysfunction without affecting the infiltration of leukocytes. The inhibition of 
chronic enhanced adenosine levels led to strongly reduced fibrosis development. This is in 
contrast to earlier findings from the BLM i.t. model in CD73-/- mice, where BLM administration 
led to enhanced inflammation and fibrosis development, indicating a protective role for 
CD73/adenosine in this acute model of lung injury [152]. These conflicting data indicate 
different roles for adenosine in acute versus chronic disease models as described later in 
more detail. 
Irradiation of CD73-/- mice led moreover to reduced expressions of the fibrotic 
mediators OPN and TGF, as well as the ECM molecules collagen and fibronectin in 
contrast to irradiated wildtype mice. TGF is a well-known and studied pro-fibrotic mediator 
and was shown to be upregulated initially after thorax irradiation of mice and during the 
fibrotic phase [124]. Inhibition of TGF resulted in attenuated fibrosis development in 
irradiated mice and reduced levels of OPN compared to untreated controls [29, 39]. OPN 
plays essential roles in the regulation of the recruitment and differentiation of fibroblasts and 
myofibroblasts [74]. The genetic loss of OPN in mice resulted in reduced levels of collagen 
type I, fibronectin and TGF [100]. Taken together the results indicate that the expression of 
CD73 and chronic accumulating adenosine after WTI triggers the expression and secretion 
of TGF and OPN, which can mutually influence each other. Subsequently TGF and OPN 
trigger fibroblast recruitment, myofibroblast differentiation, EMT and secretion of ECM 
molecules [154]. 
Moreover, we could show that treatment with PEG-ADA, to convert the extracellular 
adenosine further to inosine, or use of the CD73 antibody TY/23, to inhibit the enzymatic 
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conversion from AMP to adenosine, also effectively reduced fibrosis development and the 
expression of fibronectin. These findings support the hypothesis that the chronic 
accumulating adenosine, and not CD73 itself, is the main driver of RILF. 
These data give new possibilities in the prevention of late adverse effects of radiation 
treatment in the thoracic region. Of special interest is in this sense PEG-ADA as it is already 
successfully used since years in the treatment of ADA deficiency in patients [42]. The 
integration of CD73 antibodies into the clinics is another promising approach to widen the 
therapeutic window of tumor treatment with radiation. It has been shown that various tumor 
types express CD73 on their surface (reviewed in [1]). Like on Treg, CD73 expression on 
tumor cells is also associated with immunosuppressive capacities, thereby helping the tumor 
cells to escape the host immune system and in worst case reeducate the host immune cells 
to support tumor growth and invasiveness [5, 136]. Consequently, the treatment of patients 
with CD73 antibodies could help on the one hand, to protect from early and late adverse side 
effects of irradiation as shown by us, and on the other hand, blocking CD73 on tumor cells 
could potentially help to sensitize the immune cells to the tumor cells and increase their 
eradication [53]. Furthermore, own preliminary data and data from other groups showed that 
genetic loss of CD73 reduces the metastatic potential of tumor cells [135, 136, 168]. Patient 
studies confirmed, that in metastatic tumors CD73 levels are increased [76]. 
Extracellular adenosine can either be transported via ENTs into target cells, undergo 
conversion into inosine or it can signal via four different adenosine receptors (for details see 
section 1.4.1). Current knowledge about the role of the different receptors in fibrotic diseases 
is mainly based on studies using BLM-induced lung injury models and ADA deficient mice. 
Like already mentioned in the introduction the i.t. BLM model triggers acute injury whereas 
the i.p. BLM and ADA-/- model cause chronic tissue injury and enhanced levels of adenosine 
[23]. The project now reveals differences in the results obtained from acute and chronic injury 
models. The i.t. BLM model in CD73-/- mice caused exaggerated lung inflammation and 
fibrosis [152], whereas loss of CD73 in the radiation model protected from early damage and 
reduced fibrosis establishment. The differential results from the acute and chronic disease 
models of CD73-/- mice suggest also distinct contributions of the adenosine receptors in the 
respective disease model. Therefore, the role of the adenosine receptors in the radiation-
induced lung injury model is under current investigation in our lab. 
It was shown that a double knockout of ADA and ADORA1 resulted in enhanced 
inflammation and damage of the lung, thereby attributing anti-inflammatory functions to the 
A1 receptor [141].  
In a study with ADA and ADORA2A double knockout mice it was shown that deletion 
of the A2A receptor resulted in elevated inflammation and chemokine expression in the 
corresponding lungs [98]. Challenging ADORA2A knockout (ADORA2A-/-) mice with i.t. BLM 
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resulted in a high mortality rate of the mice during the initial inflammatory phase, led to 
elevated numbers of inflammatory cells in the BAL and enhanced tissue damage [130]. Both 
studies suggest a protective role for adenosine signaling via ADORA2A upon acute and 
chronic tissue damage.  
The functions of adenosine signaling through the low affinity receptor ADORA2B are 
reported to be controversial. As the receptor has a rather low affinity for adenosine it is 
suggested that binding of adenosine to ADORA2B takes mainly place during chronic 
inflammatory phases where long lasting high levels of adenosine exist [130]. ADORA2B 
expression was shown to be enhanced in ADA-/- mice and pharmacological targeting of 
ADORA2B resulted in reduced lung inflammation and fibrosis. Moreover, the expression of 
the pro-fibrotic mediators TGF and OPN was reduced [142]. Another study compared the 
role of ADORA2B in acute and chronic lung injury BLM models. While genetic deficiency of 
the ADORA2B in the BLM i.t. model led to an elevated acute lung injury and slightly 
reduction of fibrosis development, ADORA2B-/- mice that were exposed to BLM by i.p.-
injections showed a mild inflammatory phase and a significant reduction in fibrosis 
development [174]. On the other hand, pharmacological inhibition of ADORA2B in a BLM i.t. 
model dampened levels of lung fibrosis and pulmonary inflammation, indicating that 
adenosine had not only protective roles [142]. In conclusion, signaling via the ADORA2B 
receptor seems to vary substantially between acute and chronic injury of the lung tissue. 
Genetical or pharmacological targeting of the ADORA3 receptor in ADA-/- mice could 
dampen pneumopathy, indicating a pro-inflammatory role for the A3 receptor in pathogenesis 
[169]. In the acute injury model ADORA3 knockout (ADORA3-/-) mice showed enhanced 
inflammation after BLM administration. Although ADORA3 seems to have an anti-
inflammatory role during the acute injury no change in fibrosis development was observed 
[101]. 
From what is known from chronic disease models it can be speculated that radiation-
induced pneumopathy might be exaggerated in ADORA1 and ADORA2A deficient mice. In 
contrast ADORA2B or ADORA3 deficiency might reduce disease development after WTI. In 
line with this speculation, unpublished microarray data from irradiated versus non-irradiated 
wildtype mice revealed elevated expression of ADORA3. Furthermore, preliminary 
quantitative real-time PCR (QPCR) data from whole tissue RNA samples confirmed 
enhanced levels of ADORA3 but also slightly enhanced levels of ADORA2B. First data from 
an own study with ADORA2A-/- mice indicate that loss of ADORA2A leads to high numbers of 
infiltrating immune cells to the lung tissue and a worsened fibrosis after WTI. Preliminary 
histologic data of irradiated ADORA2B-/- mice indicate reduced fibrosis development 
compared to wildtype mice, supporting our hypothesis and results from the chronic disease 
models. 
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4.2 The role of lymphocytes 
WTI triggered an initial loss of T cells in the irradiated lung tissue but also 
systemically in the spleen and lymph nodes. Subsequently, potentially through 
cytokine/chemokine-induced recruitment by resident cells and activated innate immune cells, 
CD4+ T cells infiltrated into the lung tissue at 6 weeks post-irradiation. The infiltration of CD4+ 
T cells was also observed in patients with symptomatic pneumonitis and in other murine 
studies [63, 105, 121]. It has been suggested that the early infiltration of T cells is linked to 
late adverse side effects of WTI. In an experimental study with depletion of CD4+ T cells in 
rats early upon IR resulted in decreased fibrosis development, indicating a disease 
promoting role for CD4+ T cells [107]. In contrast, previous data from our lab showed that the 
absence of mature T and B cells in in RAG2-/- mice worsened fibrosis, indicating also 
protective effects of lymphocytes in normal tissue toxicity [17, 157]. 
As the infiltration of CD4+ T cells seemed to be a pathologic feature of radiation-
induced pneumonitis we characterized these cells in more detail. Treg are characterized by 
their high CD25 expression and at least in mice, by the transcription factor Forkhead-Box-
Protein P3 (FoxP3). Treg are known to be immunosuppressive and execute important roles 
in the regulation and dampening of inflammatory responses [126, 162]. We found elevated 
levels of Treg 3 weeks upon IR in the lung but also in lymph nodes and spleen of irradiated 
mice. The Treg seem to dampen the inflammatory response of CD4+ effector cells at the very 
early time point after irradiation resulting in a delayed onset of pneumonitis. Enhanced levels 
of Treg were additionally found during the fibrotic phase 24 to 30 weeks post irradiation. 
Besides TGF and CTLA-4, the expression of CD73 on Treg is associated with their 
immunosuppressive capacity [30, 109]. Furthermore, adenosine signaling via ADORA2A was 
shown to drive Treg induction and proliferation, so that the elevated levels of Treg during the 
pneumonitic and fibrotic phase might be due to high extracellular adenosine concentrations 
[109]. As Treg can also be induced by TGF [118], which is found initially after lung injury 
and during the fibrotic phase, their appearance could be related to the pro-fibrotic mediator 
TGF [70, 72, 124]. Treg were shown to secrete TGF, a mechanism by which they could 
drive fibrotic actions [79, 80]. A recent study showed that the presence of Treg in a murine 
model of BLM-induced lung injury aggravated lung fibrosis [8]. In a radiation-induced lung 
injury model depletion of Tregs with an anti-CD25 antibody inhibited fibrocyte recruitment 
and reduced fibrosis development [166]. 
Since we found elevated levels of B220+ cells, presumably B lymphocytes, at 12 
weeks after RT there might be an important role also for B cells in disease progression which 
needs to be further addressed but was not investigated in the present project. 
The data on T-lymphocytes strongly suggest important roles for effector T cells as 
well as Treg in the pathology of radiation-induced pneumonitis and fibrosis. Therefore, 
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studies to define their roles for radiation-induced pneumopathy are under current 
investigation in our lab. Nevertheless, the focus of my project was the myeloid compartment 
of immune cells and their impact especially on RILF. 
4.3 The role of myeloid cells 
It has been shown that WTI triggers the secretion of pro-inflammatory cytokines and 
chemokines that lead to the infiltration of monocytes and macrophages in patients as well as 
murine studies [17, 63, 85, 125]. Our present results confirm a repopulation of pulmonary 
macrophages after a drastic reduction especially of alveolar macrophages initially after 
radiation treatment. Moreover, during the pneumonitic phase lung macrophages showed 
enhanced expression of the pro-inflammatory marker major histocompatibility complex class 
II (MHCII). As pulmonary macrophages are the first line of defense and one of their main 
tasks upon damage is to phagocyte cell debris and apoptotic cells, it is more than reasonable 
to find activation markers upregulated [12]. Interestingly, MHCII remained (slightly) enhanced 
throughout the observed period up to 30 weeks in the irradiated wildtype mice, indicating a 
chronically inflamed micromilieu upon thorax irradiation. In contrast to MHCII, the anti-
inflammatory marker macrophage mannose receptor (MMR) was elevated during the early 
pneumonitic phase on alveolar macrophages and pulmonary macrophages, but exclusively 
upregulated on alveolar macrophages during the fibrotic phase 25-30 weeks after IR. These 
observations suggested an important role for the alveolar macrophages in orchestrating pro-
fibrotic actions. The presence of alternatively activated macrophages has already been 
reported in patients with IPF and COPD [51, 173], in the model of i.t. BLM [62], and recently 
also in RILF in mice [49, 171]. But so far the contribution of alternatively activated 
macrophages, particularly to RILF, remains poorly understood. 
Although our results show that total numbers of pulmonary macrophages were not 
altered in late stages of pneumopathy upon irradiation, histological analysis revealed an 
accumulation of lung macrophages in organized clusters. The organization of macrophages 
into clusters has so far only been described in a rat model of i.t. BLM [70]. Interestingly, the 
clustered macrophages expressed pro-fibrotic markers like TGF and -SMA as well as the 
anti-inflammatory marker ARG1 but not the pro-inflammatory marker iNOS, corroborating our 
flow cytometry data. As already mentioned in the introduction, the enzymes iNOS and ARG1 
compete for the same substrate (-Arginine). Activity of ARG1 results in cell growth and 
collagen synthesis [171]. Through the expression of TGF and potentially further fibrotic 
mediators, the clustered macrophages may participate in fibrosis development by mediating 
recruitment and activation of fibroblasts and fibrocytes [165]. Taken together, the results 
suggest that the organized macrophages in the fibrotic lung tissue consist mainly of alveolar 
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macrophages as those were the ones that upregulated MMR at late stages of the disease 
and that they might contribute to fibrosis development. 
As CD73-/- mice showed attenuated fibrosis development upon WTI and alveolar 
macrophages showed enhanced expression of CD73 in wildtype mice 6-12 weeks after 
irradiation we were curious about the phenotype of macrophages in the CD73-/- mice. 
Interestingly, lung tissue analyses revealed that macrophages in CD73-/- mice were not 
organized in clusters. Besides its enzymatic function, CD73 has been shown to be important 
in lymphocyte binding to endothelial cells during extravasation as well as in the interaction 
with ECM molecules like fibronectin [3, 131]. Therefore it could be discussed whether the 
lack of macrophage clusters in CD73-/- mice might be due to reduced infiltration of 
macrophages or an up to now not proved loss of cell-to-cell interaction. However, numbers of 
pulmonary macrophages depicted by flow cytometry were not different from those of wildtype 
mice (data not shown). Thus, the infiltration of macrophages in CD73-/- mice seems not to be 
inhibited in our model. Nevertheless, we cannot exclude that CD73 itself might impact on 
macrophage clustering, although also reduced numbers of macrophage clusters were also 
found in TY/23 and PEG-ADA treated wildtype mice after WTI (data not shown). 
Phenotype analysis of lung macrophages showed that MHCII was also upregulated in 
CD73-/- mice upon irradiation. However, in CD73-/- mice the anti-inflammatory marker MMR 
was only upregulated in alveolar macrophages initially upon WTI (3 weeks), but importantly 
not during the fibrotic disease stages. These data suggest that adenosine might be an 
important driver of alternative macrophage activation and organization into clusters. In line 
with our finding, results from an in vitro study demonstrated that adenosine could promote 
alternative macrophage polarization [28]. Since macrophages can recruit fibroblasts and 
myofibroblasts, the main producers of fibrosis-associated ECM molecules like collagens and 
fibronectins [73], prevention of the switch of the macrophage phenotype may be a promising 
treatment strategy and is under current investigation in the lab. 
Our data strongly suggest that the accumulation of extracellular adenosine impacts 
either on the organization of macrophages into cluster, on their phenotype switch from pro- to 
anti-inflammatory or to both processes. Up to now it is still unclear whether adenosine can 
also in vivo directly act on the macrophages to manipulate their phenotype and the clustering 
or whether adenosine exerts its function via action on other cells in the microenvironment. As 
already mentioned above, adenosine is known to exert its functions through four different 
adenosine receptors. Identifying and targeting the involved adenosine receptor(s) might 
therefore be another option to attenuate pro-fibrotic actions of chronically accumulating 
adenosine and is under current investigation in our lab. 
From what has been discussed about adenosine receptors before it can be 
suggested, that ADORA1 and ADORA2A deficient mice undergoing WTI show an enhanced 
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pneumonitis, possibly leading to enhanced recruitment of macrophages and finally elevated 
fibrosis development or earlier onset of fibrotic actions. In line with this, own preliminary data 
indicate that loss of ADORA2A leads to high numbers of infiltrating immune cells to the lung 
tissue and a worsened fibrosis. Furthermore, it can be speculated that targeting signaling of 
adenosine via ADORA2B and ADORA3 in our radiation-induced model of pneumopathy 
might lead to mild pneumonitis and attenuated fibrosis development without the formation of 
alternatively activated macrophage clusters. Indeed, preliminary histologic data of irradiated 
ADORA2B-/- mice indicate reduced fibrosis development compared to wildtype mice. 
So far our studies with the adenosine receptor knockout mice are still ongoing and 
lack the characterization of macrophages. But a recent study wherein mice, deficient for 
ABORA2B on their myeloid cell compartment (Adora2B(f/f)-LysM(Cre)), were treated with 
BLM i.p., resulted in reduced fibrosis development, improved lung functions and reduced 
numbers of macrophages expressing alternative activation markers [66]. The study suggests 
a direct action of adenosine on macrophages via ADORA2B that results in a phenotypic 
switch of macrophages. Furthermore, the development of fibrosis is suggested to be linked to 
macrophages and their phenotype. From those data ADORA2B seems to be a promising 
candidate for the prevention of lung fibrosis development also in radiation-induced lung 
disease. 
But besides a direct action of adenosine on macrophages it is also possible that 
adenosine triggers changes in the microenvironment that lead to the polarization of 
macrophages towards an anti-inflammatory or pro-fibrotic phenotype. For example, the 
expression of the mediators TGF and OPN were reduced in irradiated CD73-/- mice 
compared to irradiated WT mice. The actions of TGF and OPN have already been 
explained in the previous section. In summary, both are important pro-fibrotic mediators 
regulating recruitment and differentiation of fibroblasts and myofibroblasts, driving EMT and 
secretion of ECM molecules. These processes are all associated with fibrosis development. 
Importantly TGF was shown to drive alternative activation of bone-marrow derived 
macrophages [46]. 
4.4 The role of hyaluronan 
Our data suggest that the presence of adenosine affects the HA pathway, as we 
could detect less HA in the lung tissue of CD73-/- mice and QPCR analyses showed 
differential expression of HA synthases in response to irradiation. So far it remains unclear 
whether this is a direct effect of adenosine or whether this is a secondary effect initiated by 
e.g. TGF or OPN and can for now only be speculated. Interestingly, we found a slight, but 
time dependent upregulation of CD44 in the CD73 deficient animals. CD44 is not only the 
receptor for HA but can also bind OPN which was dramatically reduced in CD73-/- compared 
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to WT mice upon irradiation. The upregulation of CD44 might therefore be a response to low 
levels of HA as well as OPN, a potential feedback loop mechanism. Has3 is described to 
produce HA molecules of LMW that are known to act pro-inflammatory [58, 155]. Our results 
showed an initial upregulation of Has3 in the WT mice, potentially as a mechanism to recruit 
immune cells to the injury site as it has been shown that LMW HA induces the expression of 
MIP-1, MIP-1, RANTES (regulated on activation, normal T cell expressed and secreted) 
and MCP-1 in alveolar macrophages [92]. At the same time point also the receptor RHAMM 
was upregulated. RHAMM is essential for recruitment of macrophages upon stimulation with 
LMW fragments [107, 127, 148]. Interestingly it has been shown that inhibition of RHAMM in 
rats, that were challenged i.t. with BLM, reduced the number of recruited macrophages to the 
lung tissue as well as fibrosis development [170]. These data indicate that the early 
recruitment of macrophages after lung injury impacts on fibrosis development. 
During the chronic accumulation of adenosine, no enhanced expression of Has3 was 
found in wildtype animals, instead at later time points Has3 was upregulated in CD73-/- mice. 
This observation was paralleled by the upregulation of RHAMM. It would be of interest to 
follow up the CD73-/- mice longer than 30 weeks in terms of macrophage numbers, the 
formation of macrophage clusters and their phenotype. It is postulated that signaling of 
adenosine via ADORA2A, in the early response to damage, can inhibit the upregulation of 
pro-inflammatory mediators (e.g. TNF-) that are induced by LMW HA [130]. The same 
group further showed, that upon chronic lung inflammation LMW HA could down-regulate the 
expression of ADORA2A and that this regulation was CD44-dependent [26]. In a study with 
ADA deficient mice, signaling of adenosine through ADORA2B was linked to an increased 
expression of Has1 and Has2 [67]. In line with this observation, our data showed at 12 weeks 
after RT reduced expression of Has1 and Has2 in irradiated CD73-/- mice compared to 
irradiated wildtype mice. The data indicate a connection between accumulating extracellular 
adenosine and the expression of HA synthases. In this regard our results strengthen the 
hypothesis that the extracellular adenosine might, at least in parts, influence HA-dependent 
processes. But these regulatory functions seem to be of high complexity and need further 
investigations. 
 
Finally, a schematic overview (depicted in Figure 5) will summarize my conclusion 
regarding the underlying mechanisms of radiation-induced pneumopathy with respect to 
CD73/adenosine, HA, macrophages and T-lymphocytes. 
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Figure 5: Schematic conclusion. Irradiation of 
the lung tissue leads to initial death, damage or 
stress of the affected cells. Subsequently this 
results in the release of DAMPs, cytokines and 
chemokines that recruit and activate innate and 
adaptive immune cells like neutrophils, 
macrophages and T cells. Some cells in the lung 
tissue undergo delayed damage undergo delayed damage and cell death and chronic release of soluble mediators like ATP takes 
place. Via CD39 and CD73 on the surface of various cells in the lung adenosine accumulates in the 
extracellular space. Accumulating adenosine in the irradiated lung tissue can act on multiple targets. It can 
either bind to adenosine receptors on the macrophages, T cells or to other lung cells. Signaling through e.g. 
ADORA2B on macrophages might lead to alternative activation of macrophages. Whether cluster building is 
necessary for alternative activation, alternative activation is necessary for cluster building or whether both 
processes are independent of each other remains elusive. Signaling of adenosine via ADORA2A can induce 
and activate Treg that are known to secrete TGF. Signaling of adenosine via other pulmonary cells might 
lead to changes in the micromilieu which could also drive alternative polarization of macrophages. The 
alternative activated macrophages are known to drive a pro-fibrotic and anti-inflammatory micromilieu that 
leads to the recruitment and activation of fibroblasts and fibrocytes, which are finally responsible for secretion 
of ECM molecules and development of lung fibrosis. ADORA = adenosine receptor, Teff = T effector cells. 
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5 Summary and Outlook 
Radiotherapy is an integral part of cancer treatment for patients suffering from a 
neoplasm in the thoracic region. Unfortunately, life-threatening early and late side effects of 
the healthy lung tissue limit the applied radiation dose thereby enhancing the risk of tumor 
relapses. One goal of research is the widening of the therapeutic window by protection of the 
normal tissue without protecting the tumor from irradiation or by sensitizing the tumor cells to 
radiation-induced cell death without sensitizing the normal tissue. Taken together, the results 
obtained during my PhD project provide new insights into normal tissue toxicity upon 
irradiation within the thoracic region. The data suggest new treatment options for patients 
receiving RT by immunomodulation or modulation of adenosine signaling.  
WTI in wildtype mice led to an initial loss of alveolar macrophages and elevated 
numbers of Treg at 3 weeks after IR. Fibrosis was detected 25-30 weeks after IR and was 
accompanied by the appearance of alternatively activated macrophages, which were 
organized in clusters, and increased numbers of Treg. Moreover, the data showed that 
extracellular adenosine accumulated progressively after RT in the lung tissue, which could 
be attributed to elevated CD73 activity. Targeting CD73 genetically (CD73-/-) or 
pharmacological (TY/23), or by reducing adenosine levels with PEG-ADA treatment led in all 
cases to significantly reduced expression of fibrotic markers (OPN, TGF, fibronectin, -
SMA) and fibrosis levels. Moreover, the loss of CD73 led to an altered organization and 
phenotype of macrophages during the fibrotic phase. Alternatively activated macrophages 
that were organized in clusters were not found in in CD73-/- mice. Furthermore, CD73-/- mice 
showed a modified HA signaling, that has an impact on the recruitment of macrophages 
upon tissue damage. In conclusion, the data indicate that Treg, high levels of extracellular 
adenosine and alternatively activated and in clusters organized macrophages drive fibrosis 
development after WTI. The organization and phenotypic switch of macrophages is 
presumably triggered by high extracellular adenosine levels and potentially through HA 
signaling. 
Interestingly, alternatively activated macrophages share many characteristics with 
tumor-associated macrophages that are known to drive tumor growth. Moreover, it has been 
shown that various types of tumors highly express CD73/adenosine thus having the 
capability to escape the immune system. Therefore, immunomodulation as well as the 
modulation of adenosine signaling by inhibiting CD73 are good options for an optimal 
widening of the therapeutic window in both directions, protection of the normal tissue and 
sensitization of the tumor cells. 
To gain a better insight into the underlying mechanism that trigger the phenotypic 
switch of macrophages in wildtype mice and the role of alternative activated macrophages for 
disease progression and development, several aspects can be addressed in the future. One 
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interesting aspect is the targeting (genetic and pharmacologic) of the different adenosine 
receptors to uncover whether signaling through one specific receptor triggers alternative 
macrophage activation and fibrosis development. Moreover, a repolarization of the 
macrophage phenotype to a more pro-inflammatory subtype might attenuate fibrosis 
development. Treatment experiments with a macrophage inhibitor in our model of RILF are 
still ongoing, but first preliminary results indicate attenuated fibrosis development in the 
treated mice. Another option to interfere with the pathologic effects driven by organized and 
alternatively activated macrophages offers the HA system. Preventing exaggerated 
production of LMW HA fragments after initial damage or blocking of the HA receptor RHAMM 
could reduce the number of recruited macrophages. On the other hand, enhanced production 
of HMW HA molecules at the end of the pneumonitic phase could also be a critical step for 
fibrosis development. Inhibition of HA syntheses and reduction of mRNA expression could be 
addressed by treatment with 4-Methylumbelliferone [103]. 
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ADA adenosine deaminase 
ADA-/- ADA knockout 
ADORA1 adenosine receptor 1 
ADORA2A adenosine receptor 2A 
ADORA2A-/- ADORA2A knockout 
ADORA2B adenosine receptor 2B 
ADORA2B-/- ADORA2B knockout 
ADORA3 adenosine receptor 3 
ADORA3-/- ADORA3 knockout 
ADP adenosine diphosphate 
AMP adenosine monophosphate 
ARG1 arginase-1 
ATP adenosine triphosphate 
BAL(F) bronchoalveolar lavage (fluid) 
BLM bleomycin 
CCL-2 macrophage chemoattractant protein-1 
CD39 ectonucleoside triphosphate diphosphohydrolase-1 
CD73 ecto-5-nucleotidase 
CD73-/- CD73 knockout 
COPD chronic abstructive pulmonary disease 
CSF-1 colony-stimulatin factor 1 
DAMP danger associated molecule pattern 
ECM extracellular matrix 
EMT epithelial-mesenchymal transition 
ENT equilibrative nucleoside transporter 
FoxP3 forkhead-box-protein P3 
HA hyaluronan 
Has1-3 HA synthase 1-3 
HMGB1 high mobility group box 1 protein 
HMW high molecular weight 
HSP70 heat-shock protein 70 
HYAL hyaluronidase 
i.p. intraperitoneal 
i.t. intratracheal 
i.v. intravenous 
IL-1 interleukin 1 (or any other number) 
INF- interferon-gamma 
iNOS inducible nitric oxide synthase 
IPF idiopathic pulmonary fibrosis 
IR ionizing radiation 
LMW low molecular weight 
MCP-1 macrophage chemoattractant protein-1 
M-CSF macrophage-colony stimulating factor 
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MHCII major histocombatibility complex class II 
MIP-1/2 macrophage inflammatory protein-1beta/-2 
MMR macrophage mannose receptor 
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NOS nitric oxide species 
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ROS reactive oxygen species 
RT radiotherapy 
TBI total body irradiation 
TGF transforming growth factor beta 
TLR toll-like receptor 
TNF tumor necrosis factor alpha 
WTI  whole thorax irradiation 
-SMA alpha smooth muscle actin 
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